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EXECUTIVE SUMMARY 
The high rate of transmission of blood borne viruses (BBVs) among injecting drug users 
(IDUs), and the seriousness of the resulting diseases, means that IDUs are commonly 
tested for BBVs, particularly if they attend drug treatment clinics. The assumption appears 
to be that if IDUs know their serostatus they are in a good position to protect both 
themselves and their communities by behaviour change and improved health care. Yet the 
HIV/AIDS testing literature suggests that this assumption is oversimplified, and there is 
little or no contemporary literature that examines the human factors involved in being 
tested for hepatitis C or B, or being vaccinated against hepatitis B.  
The major aim of the present study was to conduct an investigation of testing IDUs for 
hepatitis C, hepatitis B and HIV/AIDS and vaccinating IDUs against hepatitis B, from the 
perspectives of both IDUs and test service providers (SPs). Perth IDUs were recruited 
through advertising and snowballing to take part in an anonymous and confidential semi-
structured interview for which they were offered $15. SPs from every Australian 
jurisdiction were recruited through snowballing and networking to complete a faxed 
questionnaire and participate in a half hour telephone interview. The data are both 
quantitative and qualitative. 
A total of 200 IDUs,103 men and 97 women, were interviewed. Their ages ranged from 
14 to 47 years with a mean of 26.1 and a median of 24 years. The majority of respondents 
were not married or living with sexual partners, and nine out of ten respondents were 
heterosexual. Five identified themselves as of Aboriginal or Torres Strait Islander descent. 
Most of the IDU respondents had used alcohol, cannabis, hallucinogens, amphetamines, 
heroin, ecstasy, and benzodiazepines at some time. Just under half had used methadone. 
Almost all of the respondents who had used heroin or amphetamines reported injecting 
these drugs at some time. Of the 182 respondents who had ever used heroin, 96% reported 
injecting within the last year and 67% within the last month. The main drug injected by 
over three quarters of respondents was heroin.  
Around 70% of respondents had been tested for each of the three viruses an average of 7 
times, and approximately 7% had received more than 10 tests within each category. Much 
of the testing was done in batteries of all three tests. 
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Almost 60% of respondents had not been vaccinated against hepatitis B, 24% had been 
vaccinated, 9% were hepatitis B antibody positive, and 8% did not know whether or not 
they had been vaccinated. 
Thirty nine SPs were interviewed throughout Australia: half from rural and half from 
metropolitan areas. One third were recruited from each of general practices and sexual 
health clinics. Others worked in drug treatment centres, hospitals, and other agencies 
including contact tracers, prison medical services, gay and lesbian medical services, 
community health services and youth health services. These agencies saw an average of 
706 clients per month. Service providers ordered an average of 40 hepatitis C antibody 
tests, 51 hepatitis B antibody tests and 52 HIV tests a month. They also carried out an 
average of 19 hepatitis B vaccinations a month. 
Almost all IDU respondents believed that each of the BBVs was a risk for IDUs. The 
three major reasons for being tested were that the respondent had been exposed to risk in 
some way,  the test was recommended or required, and/or the respondent was concerned 
about the possibility of passing BBVs to others. A further category, only applicable to 
hepatitis B testing, was that the respondent had experienced signs or symptoms of illness. 
Reasons for not having never been tested included that the respondent believed that they 
were not at risk, they had not “got around to it” and/or they scared or nervous about test 
outcomes.  Some respondents had never heard of a hepatitis B test.  
SP informants reported that their IDU clients were offered testing if they had disclosed 
past or current injecting drug use during history taking, and/or if they self-referred for 
testing. A few said they tested IDUs routinely and some said clients were tested if there 
were symptoms present, an abnormal liver function test was detected, or as part of an STD 
screen. Over a third of SP informants said they would re-test a client every time a test was 
requested. 
One hundred and fifty testing events were described by IDU respondents. Most of these 
were descriptions of batteries of all three tests and only 17% described a first test 
experience. Most of these testing events occurred at the individual’s request.  
January 2000 National Drug Research Institute 
Drawing Blood                                                                                                                                                            ix 
For many, the experience was routine. Three quarters claimed to have received no pre test 
counselling although some said that this was because they did not want or need it. 
However, some misunderstood the question “were you offered any pre-test counselling?” 
apparently believing that this asked whether they were referred to another person or agency 
for counselling prior to being tested. Whether or not respondents received pre-test 
counselling was related to the nature of the service provider who ordered the test.  GPs 
and hospitals were reported as being less likely to have provided counselling than medical, 
sexual health and drug treatment clinics. 
All SP informants said that pre- and post-test counselling was provided for a BBV test. 
The majority reported using pre-test counselling to assess the client’s risk, discuss 
transmission and prevention, give information about the viruses, tests and window periods, 
and establish what clients would do if they received a positive result. 
IDU respondents reported that they had received their test result in a face to face interview 
with their test service provider on almost three quarters of occasions. However, on around 
one in ten occasions they had received them by telephone. Some respondents had not 
collected their results: most of these because they believed that they would be informed if 
their results were positive. 
The majority of SP informants reported that they always gave BBV results face to face but 
a few said that they were less stringent about hepatitis C and B than HIV/AIDS results, and 
were prepared to give these results over the phone. SP informants’ main explanation for 
IDUs’ failure to collect results was that they were transient and mobile.  
IDU respondents reported that no post-test counselling was given on over 80% of 
described test occasions. Provision of post-test counselling was related to the test result, 
with seropositive clients being more likely to have received counselling than those who 
were negative. Many of those who described post-test counselling, moreover, reported it 
in terms of medical advice given if they were hepatitis C positive. Only four respondents 
described post test counselling which was focussed on prevention. Respondents were 
referred to other medical or community agencies on only nine test occasions, with most of 
these referrals being to specialist medical services. Most said they did not know at the 
time about local community-based support agencies. 
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Almost all SP informants said they used post-test counselling to discuss prevention with 
clients whose results were negative. With positive results most SP informants used post-
test counselling to suggest follow-up and monitoring, including further testing and referral 
to specialists. The majority said they also discussed transmission and prevention issues 
with positive clients and referred them to specialists. One in three mentioned referring to 
alcohol and drug services, sexual health clinics, and support services. 
IDU respondents reported that on almost 40% of described test occasions they experienced 
anxiety which tended to be related to waiting for results. The majority of those whose 
results were negative said that they were pleased, relieved, or not surprised. Those who 
received positive test results were almost equally divided between being 
upset/angry/concerned, not surprised or focused on their state of illness or health. 
SP informants had observed a wide range of emotional states in their BBV tested clients, 
but anxiety predominated. Most said they dealt with these reactions with counselling but 
one in three said they provided more information, and some referred these clients. 
IDU respondents who had been tested at least once were asked if they had changed their 
behaviour in any way subsequent to their last test. The majority of respondents, regardless 
of the test outcome, had not changed their behaviour, with the most common reason for 
this that they were “already safe”. 
Almost half of IDU respondents said that they knew little or nothing about hepatitis B 
vaccination. Many of those that had not been vaccinated had never heard of it or did not 
realise that such a vaccine was available and/or no-one had ever suggested they should be 
vaccinated or offered them the opportunity. The most common reason given for being 
vaccinated was that it was suggested by a doctor or clinic staff. 
All SP informants believed that IDUs needed to be advised to be vaccinated and half said 
that vaccination came about mainly as a result of their recommendation. Some thought 
that vaccination needed to be pushed more. 
The implications of these data are discussed in terms of the NHMRC guidelines when 
testing for hepatitis C. These lay out standards for pre- and post-test counselling and 
suggest that the outcomes of counselling should be the provision of psychosocial support, 
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prevention of the transmission of hepatitis C and the optimisation of treatment outcomes. 
Our data suggest that, in the main, only the last of these outcomes was being met. Much of 
the counselling suggested in the guidelines was not occurring, and post-test counselling 
was primarily used after positive results as a medical intervention. While a range of 
emotional experiences related to being tested was described by IDU respondents, very few 
were referred to local support agencies such as the Hepatitis C Council. The testing 
process, as described by our IDU respondents, did not actively encourage seronegative 
IDUs to initiate behavioural change, nor did it encourage seropositive IDUs to regard their 
normal behaviour as behaviour which might transmit infection to others. 
Reported low levels of vaccination  are also a concern. Most of the respondents in this 
study had been tested because they were IDUs, but few had been vaccinated, even though 
many of these had received a negative hepatitis B test. It appears that opportunities for 
prevention of this disease had been squandered.  
Testing for BBVs provides an ideal opportunity in which doctors and other service 
providers can help IDUs to make the behaviour changes necessary to prevent these 
infections, or to prevent reinfection and/or other complications associated with infection. 
It is also an opportunity to inform and advise IDUs about vaccination. Since so many 
IDUs are tested, the potential for incidence reduction and secondary prevention is 
enormous. 
We believe that more information is needed from doctors, IDUs and other relevant parties 
about the limitations and difficulties with existing current pre-and post-test counselling 
guidelines when testing IDUs who may receive multiple tests. We have recently received 
funding to undertake a further in-depth examination of clinical and practical difficulties 
with these. The findings of the two studies should enable the development of specific 
recommendations on maximising the efficacy of the testing process to prevent and limit the 
spread of blood borne viruses among injecting drug users in Australia. 
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INTRODUCTION 
Given the high rates of transmission of hepatitis C and hepatitis B among Australian 
injecting drug users (IDUs), the need to monitor HIV/AIDS in IDUs because of major 
epidemics in other countries, and the seriousness of the resulting diseases, it is not 
surprising that most Australian IDUs have been tested for hepatitis C, hepatitis B and 
HIV/AIDS. In the 1994 Australian Study of HIV and Injecting Drug Use (ASHIDU)1, for 
example, 79% of IDU respondents had been tested for hepatitis C, 81% had been tested for 
hepatitis B and 91% had been tested for HIV/AIDS. These results were influenced by age 
and treatment status, such that older IDUs and/or those who had been in treatment were 
more likely to have been tested, but nevertheless, more than half of those under 24, and/or 
those who had never been in treatment, had been tested for all three viruses (Loxley, 
Carruthers & Bevan, 1995).  
A considerable literature exists in relation to human factors involved in testing for 
HIV/AIDS, but there appears to be little or no literature related to human factors in testing 
for hepatitis C and hepatitis B or vaccinating against hepatitis B. In discussing testing for 
HIV/AIDS, Beardsell (1994) pointed out that while UK HIV/AIDS test policies appeared 
to be based on the assumption that there was a correlation between HIV/AIDS 
testing/counselling and behaviour change, that assumption was simplistic and failed to take 
account of the complexity of sexual and drug using behaviours, and the range of 
motivations for participation in testing. She cited a review of twelve studies of testing and 
injecting drug use which found that behaviour changes were not linked to knowledge of 
HIV/AIDS status. She also noted that “a negative result may lead to a false sense of 
security that may sustain or even increase these [risky] behaviour patterns” (p. 10). 
Phillips and Coates (1995) found that social stigma and fear of discrimination, the potential 
for adverse consequences in social relationships if a positive HIV/AIDS result was 
returned, concerns about coping with test results, perceived lack of risk or need for testing 
and privacy concerns were all barriers to testing for HIV/AIDS. They asserted that 
research should investigate not only the initial decision to be tested, but also follow-
                                                 
1 A national study of 872 IDUs recruited in four capital cities 
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through, and focus on elucidating factors which prevented people at risk from seeking 
counselling and testing. Phillips and Coates were also concerned with the role of 
healthcare providers in encouraging or discouraging testing, and maintained that the 
impact of counselling and testing on youth should be studied.  
Lindan, et al (1994) investigated HIV/AIDS testing among alcoholics and drug users. 
They concluded that there was substantial misunderstanding or misreporting of test results, 
and maintained that this ..."underscores the need to improve testing and counselling 
procedures in this group" (p. 1155).  
These reports suggest that being tested for HIV/AIDS, at least, is not necessarily a valuable 
or useful experience for testees. Research over some years into the relationship between 
injecting drug use and BBVs at this Institute has led to some similar conclusions. The 
thrust of our concern is that failure to take account of the complex human factors involved 
in testing can either deter individuals from presenting for testing, or render testing 
ineffectual for both the testee and her/his community. The following are some examples 
that have emerged from our research:  
• In the Australian National AIDS and Injecting Drug Use Study (ANAIDUS), some 
respondents failed to understand the question: "Have you ever received a positive test 
result?". The most probable misinterpretation of the question was as "Have you ever 
been cleared of being infected with HIV/AIDS?" (Loxley, 1991).  
• In a study of young IDUs, the motivation for HIV/AIDS testing was not normally that 
respondents believed they had put themselves at risk, but more to prove to other people 
that they were not infected. Testing did not usually result in behaviour change. The 
decision to be tested was difficult for some, and the process of testing intimidating for 
others, so much so that some respondents assumed their own HIV/AIDS status on the 
basis of others' because they were unwilling to be tested. Some respondents were 
unaware of services provided for testing, and others did not understand the meaning of 
the test results. A few respondents were unwilling to collect test results because they 
were afraid of the outcome (Loxley, 1998). 
• In the same study, Ovenden and Loxley (1993) found that fewer than half of all 
respondents who had been tested for HIV/AIDS by their General Practitioner received 
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pre- and post-test counselling which met the Australian Medical Association and Royal 
Australian College of General Practitioners guidelines. Some doctors had not received 
informed consent, and the giving out of results over the phone or by receptionists was 
common.  
• A substantial proportion of respondents in the ASHIDU were uncertain about the 
meaning of a positive antibody test for hepatitis C, hepatitis B and/or HIV. 
Approximately 10% reported not understanding the meaning of a positive hepatitis (B 
or C) test, while 5% did not understand the meaning of positive HIV/AIDS test. 
Nearly 20% of respondents thought that a positive HIV/AIDS test indicated that the 
individual had AIDS. A small proportion believed that a “positive” test meant the 
person tested had not been exposed to the virus. Most respondents had had multiple 
HIV/AIDS tests with evidence in some of considerable levels of over-testing (the 
maximum reported number of tests was 60). Self-reported BBV serostatus and 
hepatitis B vaccination status were inconsistent across multiple measures, and with 
serology undertaken for the study (Loxley, Carruthers & Bevan, 1995). 
These results suggest that there are issues relating to testing for BBV among IDUs which 
bear further and more specific examination. In particular, there is a need to investigate the 
process of testing IDUs for hepatitis C and B vaccinating them against hepatitis B, because 
there appears to be no contemporary research around this issue. The research reported here 
was funded by the Australian National Health and Medical Research Council to address 
these concerns. 
The major aim of the study was to conduct an investigation of issues from the perspectives 
of both IDUs and test service providers (SPs) relating to testing IDUs for hepatitis C, 
hepatitis B and HIV/AIDS and vaccinating IDUs against hepatitis B. Specific objectives 
were:  
• to develop a questionnaire to assess behavioural, cognitive and affective aspects of 
IDUs’ decision to be tested, the test process and test outcomes, and similar issues 
relating to vaccination.  
• to recruit a sample of at least 200 IDUs, stratified for age and experience in drug 
treatment, and administer the questionnaire in individual face-to-face interviews.  
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• to recruit a sample of SPs from every Australian jurisdiction and interview them by 
telephone about their views and experiences of testing IDUs for BBVs.  
• to offer each IDU respondent education and information about testing for BBVs.  
• to make recommendations for future interventions and research in this field. 
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METHODS 
OVERVIEW 
Two hundred Perth IDUs were recruited through advertising and snowballing to take part 
in an anonymous and confidential semi-structured interview for which they were offered 
$15. Thirty nine SPs from every Australian jurisdiction were recruited through 
snowballing and networking to complete a faxed questionnaire and participate in a half 
hour telephone interview. Quantitative data were analysed with SPSS 6.0 (Norusis, 1993) 
and qualitative data with QSR NUD*IST version 4.0 (Qualitative Solutions and Research Pty. 
Ltd, 1997). All processes and methods were approved by the Curtin University Human 
Research Ethics Committee before the commencement of data collection. 
INSTRUMENTS 
The development of questionnaires and interview guides was informed by the literature, 
previous research at this Institute, and input from a Steering Group which was made up of 
various experts in the blood borne virus (BBV) field in Perth (see Appendix 1). The IDU 
questionnaire was piloted with IDUs in residential rehabilitation, and the SP questionnaire 
was piloted with SPs in metropolitan Perth. Copies of all questionnaires and interview 
guides can be seen in Appendix 2.  
RECRUITMENT 
Injecting drug users were recruited in Perth in three phases through advertising and 
snowballing. In the first phase local drug treatment agencies, sexual health clinics and 
needle exchanges distributed fliers advertising the study. In the second phase, fliers were 
distributed around university campuses, and cafes and clothing stores. In the third phase 
an advertisement was placed in a local free music and entertainment magazine. In each 
case recruitment materials stated that IDUs who had injected in the previous 12 months 
were sought for an anonymous and confidential 30 minute interview about their drug using 
experiences, for which they would be paid $15. A name and mobile phone number were 
given to make appointments for interview.  
ASHIDU had demonstrated that younger IDUs were less likely to have been in treatment 
than older IDUs (Loxley, Carruthers & Bevan, 1995) and we assumed that they were 
therefore less likely to have been tested. We consequently deliberately over sampled IDUs 
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under the age of 20 so that there would be adequate numbers of respondents who had never 
been tested. It was our intention that not more than 50% of the sample would be aged over 
20 and/or not more than 50% of the sample would have been in treatment for drug-related 
problems. 
We attempted to recruit four metropolitan and four rural test SPs in each State and 
Territory. Known BBV health professionals across Australia were used to assist in the 
recruitment of informants through snowballing and networking. Potential informants from 
an initial list of names were approached to see whether they conformed to the inclusion 
criteria of having contact with IDUs and doing BBV testing, and would be willing to 
participate in the study which involved completion of a faxed questionnaire and a half hour 
telephone interview. Those who did not fit the criteria were asked to suggest others who 
did. There were no refusals.  
DATA COLLECTION 
IDU respondents were interviewed on site at one of three agencies. Interviews were tape 
recorded where permission to record was obtained, and later transcribed from notes and 
tapes. The data were collected during the latter part of 1997 and early 1998.  
A four page questionnaire containing questions about agencies, testing practices, staff 
training and staff knowledge of BBV was faxed to SP informants with a choice of follow 
up interview times. Telephone interviews took approximately 30 minutes and were 
transcribed from notes. The data were collected during the first half of 1997.  
ANALYSIS 
Quantitative data for both IDUs and SPs were analysed with SPSS 6.0. Most of the analysis 
was descriptive, although some statistically significant bivariate data are presented. 
Qualitative data in the IDU study were transcribed and introduced into QSR NUD*IST 4.0 
before being coded. First-level coding took place along the lines delineated by the 
questionnaire structure; further levels of coding explored themes emerging from the spread 
of responses given by respondents to these questions. These themes are presented with 
both typical responses and responses indicative of the range for any given line of 
questioning. SP data were transcribed and summary tables created for each interview 
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questions. The presentation describes the range of responses for relevant lines of 
questioning. 
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RESULTS 
Results are grouped into four broad sections: a description of each study group; events and 
decisions leading up to the test event (referred to as the decision to be tested); the test event 
itself (referred to as the test process) and the consequences of the test event. In each 
section, data are presented first for IDUs and then for SPs. 
DESCRIPTION OF INJECTING DRUG USER RESPONDENTS  
Two hundred IDUs were interviewed: 96 (48%) of these were female and 104 (52%) were 
male. Almost all (92%) identified as being heterosexual: there were 7 male and 12 female 
respondents who identified as homo- or bi-sexual. The majority (79%) of respondents 
were not married or living with sexual partners. The age range was 14 to 47 years, with a 
mean of 26.1 and a median of 24 years. The age quota was not met, with only 31% of the 
group being 20 years or younger. 
The majority (87%) of respondents were born in Australia and five identified themselves 
as of Aboriginal or Torres Strait Islander descent. The second most frequent (8%) place of 
birth was the United Kingdom or Ireland. Most respondents (98%) reported that English 
was the main language spoken in the home in which they grew up. 
Almost half (45%) of respondents had no education beyond Year 10. Of the remainder, 56 
(28%) had completed some or all of Years 11 and 12, and 53 (27%) had completed some 
or all of some form of tertiary education. The majority (64%) were unemployed; 16% 
were in part time or casual employment and 8% were in full time work. Thirteen percent 
were secondary or tertiary students. The most frequent job description given by those who 
were employed was salesperson (30%), followed by labourer (26%) and tradesperson 
(15%).  
The main source of income for 47% of the study group was unemployment benefits 
followed by other government benefits (28%). Only one in five cited employment as their 
primary source of income.  
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Fifty six percent reported having received treatment at least once for substance related 
disorders. Younger respondents (those 24 years of age or less) were significantly less 
likely than older respondents (those over 24 years)2 to have been in treatment (35.8% vs 
78.7%; p < .001). Forty-one percent of respondents were engaged in treatment at the time 
of interview, and again there was a significant age difference (18.9% of younger vs 66.0% 
of older, p < .001).  
Respondents were asked which drugs they had ever used, whether they had ever injected 
the drugs they had used; whether they had injected that drug within the last year and 
whether they had injected that drug within the last month. Results are presented in Table 1 
below. 
Table 1: Drugs ever used, ever injected, injected in last year and injected in last 






(If Ever Used) 
Injected in Last 
Year 
(If Ever Used) 
Injected in Last 
Month  
(If Ever Used) 
 n % n % n % n %
Alcohol 199 99.5 7 3.5 4 2.0 1 0.5
Cannabis 199 99.5 1 0.5 1 0.5 0 0.0
Hallucinogens 195 97.5 45 23.1 15 7.7 3 1.5
Amphetamines 193 96.5 182 94.3 137 71.0 53 27.5
Heroin 182 91.0 181 99.5 175 96.2 122 67.0
Ecstasy 159 79.5 49 30.8 15 9.4 4 2.5
Benzodiazepines 130 65.0 35 26.9 23 17.7 5 3.8
Methadone 91 45.5 30 33.0 15 16.5 7 7.7
Steroids 5 2.5 3 60.0 2 40.0 0 0.0
Other 16 8.0 2 12.5 1 6.3 1 6.3
Table 1 shows that most respondents had used alcohol, cannabis, hallucinogens, 
amphetamines, heroin, ecstasy, and benzodiazepines at least once. Just under half had 
used methadone. Steroid use was relatively uncommon.  
                                                 
2 These age groups are consistently used to characterise ‘younger’ and ‘older’ respondents._ 
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Almost all of the respondents who had used heroin or amphetamines reported injecting 
these drugs at some time. Of the 182 respondents who had ever used heroin, 96% reported 
injecting within the last year and 67% within the last month. Seventy-one percent of 
respondents who had ever used amphetamines reported injecting within the last year and 
28% within the last month.  
Half of the respondents had last injected within the week preceding the interview while 
only 20% had last injected longer than 3 months prior to the interview. The main drug 
injected by over three quarters (78%) of respondents was heroin. The only other preferred 
drug nominated by more than 3% of the group was amphetamine (19%).  
Twenty percent of respondents had been injecting for fewer than 2 years, one third 
between 2 and 5 years, 20% between 6 and 10 years, and the remaining 28% for over 10 
years. 
One hundred and forty two respondents (71%) had been tested at least once for at least one 
of the BBVs of interest to this study. The number of times respondents had been tested for 









0 1 2 3 4 to 5 6 to 10 > 10
Number of times tested
HCV HBV HIV
 
Figure 1:  Number of times respondents tested by BBV (n = 142) 
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Seventy percent of respondents had been tested an average of 5.6 (median 4) times for 
hepatitis C; 68% had been tested an average of 5.8 (median 3) times for hepatitis B and 
70% had been tested an average of 6.4 (median 4) times for HIV/AIDS. Between 6 and 
7% of respondents had received more than 10 tests for each BBV. 
Younger respondents were less likely than older respondents to have been tested for 
hepatitis C (49.1% vs 93.6%; p < .001), hepatitis B (50% vs 88.3%; p < .001) or 
HIV/AIDS (49.1% vs 94.7%, p < .001).  
The mean and median times elapsing since the first and last test for each BBV is shown in 
Table 2.  
Table 2: Months elapsed since first and last BBV test (n = 142) 
 Months Elapsed Since First Test Months Elapsed Since Last Test 
 n Mean Median Range n Mean Median Range
Hepatitis C 137 47.6 46.0 1-135 139 10.7 6.5 1-75
Hepatitis B 133 63.3 58.0 1-238 135 15.3 7.0 1-142
HIV/AIDS 139 58.3 58.0 1-168 140 10.7 6.5 1-132
Two thirds of first hepatitis C tests, and 57% of first hepatitis B and HIV/AIDS tests had 
been had been undertaken during the previous five years. The most recent tests had been 
undertaken within the last three months for approximately 40% of all those tested. The 
frequency of testing is shown in Table 3.  
Table 3: Frequency of testing 
 
Frequency of Testing 
 HCV         
(n=139) 




 n % n % n % 
Once a year or less 36 25.9 32 24.4 37 26.4 
At 4-6 monthly intervals 27 19.4 22 16.8 26 18.6 
At 1-3 monthly intervals 16 11.5 11 8.4 15 10.7 
Tested once/not tested since 25 18.0 26 19.8 25 17.9 
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No longer tested/bad veins 4 2.9 5 3.8 5 3.6 
Irregularly/ not enough/ 
rarely 
12 8.6 16 12.2 13 9.3 
At risk/reason to get tested 7 5.0 6 4.6 8 5.7 
Not specific/other 12 8.6 13 9.9 11 7.9 
Table 3 shows that approximately a quarter of all respondents tested for each virus 
indicated they were tested annually or less frequently, while about a fifth said testing 
occurred every 4 to 6 months. One in ten respondents were tested at least every three 
months. Just under 20% reported that they had only been tested once. 
Most testing had been carried out in batteries of at least two BBV tests, and a majority of 
respondents had never had a test for a single BBV. The most recent test experience for 
85% of those who had been tested was a battery in which they were tested for all three 
BBVs. Of the 22 who did not receive a battery of tests on the last occasion, 15 were 
seropositive for at least one BBV, but many of these received that diagnosis after the last 
test so that seropositivity was not the reason for not undergoing a full battery. A more 
common reason was that the respondent had been vaccinated against hepatitis B which 
made the hepatitis B test irrelevant.  
The types of agencies which provided the most recent tests are shown in Figure 2, in which 
test occasions, rather than individuals, are enumerated.  
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Figure 2:  Service providing most recent test(s) (n = 150) (DT = Drug treatment, 
SH = Sexual Health) 
Figure 2 shows that more than half of the tests were provided by GPs, with a majority of 
the remainder being provided in drug treatment agencies and clinics. 
Fifty eight respondents (41% of those who had been tested) reported being antibody 
positive to one or more virus: 56 reported that they were hepatitis C positive; 12 that they 
were hepatitis B positive and 2 that they were HIV positive. The relationships between 
reported seropositivity for the different viruses are shown in Figure 3.  
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Figure 3: Self-reported seropositivity for hepatitis C, hepatitis B and HIV:  
IDU respondents (n = 58) 
Figure 3 shows that a majority of those reporting hepatitis B positivity, and both of those 
reporting HIV positivity were also positive for hepatitis C. The majority of those reporting 
hepatitis C, however, were not positive for the other viruses.  
DESCRIPTION OF SERVICE PROVIDER INFORMANTS  
There were 39 SP informants drawn from every State and Territory. They were almost 
evenly divided between rural (51%) and metropolitan locations (49%) but we were not 
able to recruit four in each of metropolitan and regional areas in every jurisdiction as 
planned (Table 4).  Table 5 shows the distribution of SP informants by their jurisdiction 
and type of agency. The majority were drawn from general practice (GP) and Sexual 
Health Clinics (SH). Fewer came from drug treatment centres (DT), hospitals (Hosp) and 
other services (contact tracer, prison medical service, gay and lesbian medical service, 
community health service, youth health service). There were some jurisdictional 
differences, with more GPs being recruited in SA and WA, and more SPs from sexual 
health clinics being recruited in NSW.  
Table 4: Distribution of SP informants by jurisdiction and location type 
State/Territory Metro Regional Total 
ACT 4  4 
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NSW 2 4 6 
NT 2  2 
QLD 4 3 7 
SA 4 4 8 
TAS 1  1 
VIC 2 3 5 
WA 3 3 6 
Total 22 17 39 
Table 5: Distribution of SP informants by agency type and jurisdiction 
State/Territory GP SH DT Hosp Other 
ACT 1 2 1 0 0 
NSW 2 3 1 0 0 
NT 0 2 0 0 0 
QLD 1 2 2 0 1 
SA 4 1 1 0 2 
TAS 0 1 0 0 0 
VIC 2 1 0 0 2 
WA 3 1 1 2 0 
Total 13 13 6 2 5 
 
The number of agency staff involved in testing for BBV ranged from 1 to 24 (mean 6.4). 
An average of 706 (range 3 - 4000, median 2002) clients3 were seen by the agencies per 
month, with an average of 37% (median 51%) of clients disclosing that they were IDUs.  
                                                 
3 The term ‘clients’ is used consistently, although some referred to testees as ‘patients’ 
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Most (56%) of the SPs described their client group as members of the general community, 
and only the drug treatment agencies and one GP described their client group as IDUs. 
The gender balance of clients being tested was generally relatively even.  
In almost every case, IDU clients were more likely to self-refer for testing than be referred. 
On average, 85% of BBV clients were said to self-refer.  
The number of tests ordered each month for hepatitis C (antibody), hepatitis B (surface 
antigen, antibody and/or core), and HIV/AIDS and/or vaccinations against hepatitis B can 
be seen in Table 6 which shows that there was considerable variation in the number of tests 
and vaccinations ordered by participating agencies or providers per month, but similar 
numbers of tests for HIV/AIDS and hepatitis B were ordered. Fewer hepatitis C tests were 
ordered overall. Most informants reported that they ordered hepatitis B surface antigen, 
antibody and/or core tests depending on the circumstances, although a substantial minority 
ordered only the first two of these.  
Table 6: BBV tests and vaccinations ordered per month by SP informant 
agencies 
 mean median range 
Hepatitis C 40.4 175 0-350 
Hepatitis B 51.3 175 0-350 
HIV/AIDS 51.5 177 2-350 
Vaccination 18.7  75 0-150 
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The relationship of the number of tests and vaccinations to agency type can be seen in 
Table 7.  
Table 7: Mean number of BBV tests and vaccinations ordered per month by SP 
informant agencies, by agency type 
Agency type mean # 
hepatitis C tests 
mean # 





GP 11.5 10.7 13.6 6.8 
Sexual Health 69.7 92.5 88.6 25.6 
Drug Treatment 27.8 36.0 40.1 30.5 
Hospital 106.0 103.0 103.0 1.0 
Other 16.4 31.2 31.2 17.2 
Table 7 shows that overall the two hospital clinics ordered the most tests while the GPs 
ordered the least number of tests, but that both of these agency types ordered similar 
numbers of tests for each virus. Other agencies ordered more HIV/AIDS and hepatitis B 
than hepatitis C tests: the reason for this is not clear but may relate to high rates of 
diagnosed hepatitis C (and hence less testing) in the target populations. The drug treatment 
and sexual health clinics ordered the most vaccinations.  
Professional staff at the majority (86%) of the agencies received training on BBVs but 
fewer (59%) of the agencies offered training on IDU issues. BBV training consisted 
mainly of courses, seminars, workshops, conferences and journal reading. In-service 
training from senior staff or visiting specialists was mentioned, as were staff meetings, 
Continuing Medical Education (CME) activities for doctors and self directed learning. 
IDU training consisted of journal reading, conferences and seminars, updates from 
specialists, in-service, staff meetings and self directed learning. Some SP informants also 
said they received information from non-government organisations, clients and the 
community. 
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Almost a half of SP informants were familiar with the NH&MRC Guidelines for hepatitis 
C, over a third were not and a few knew of their existence but were not familiar with them. 
However only one in three of those that said they were familiar with the guidelines had 
read them. This means that approximately 15% of SP informants had actually read the 
guidelines. 
THE DECISION TO BE TESTED 
This section describes the background to the decision to be tested or not tested from the 
perspectives of the IDU respondents and the SP informants.  
Perceptions of BBV Risk to IDUs  
In order to help assess the motivations of IDU respondents for being tested and their 
expectations of the testing process and its consequences, they were asked whether they 
believed each of the three BBVs under study was a risk for IDUs.  Almost all IDU 
respondents believed that each of the BBVs was a risk for IDUs. Reasons given for this 
belief were very similar for hepatitis C and HIV/AIDS with around three quarters citing 
the role of sharing, and one in three simply mentioning “blood” as a risk factor. Unsafe 
sex was mentioned as a risk for both hepatitis C and HIV by 12%. An additional risk of 
Hepatitis C was its prevalence, mentioned by 17%.  
[It’s] more of a risk than HIV – there’s more people in the community that carry hepatitis C – 
you’re going to come in contact with more hepatitis C carriers than HIV carriers 
 (28 year old woman) 
Hepatitis B was a little different: while similar numbers thought it was risky, there was less 
certainty about why. Around half thought sharing was a risk, a further quarter mentioned 
blood, and 12% mentioned prevalence, but 20% said they did not know much about it. 
Reasons for Being Tested 
All IDU respondents (n = 142) who had been tested for one or more BBVs were asked 
“Why did you decide to get tested for [the BBV in question]”. Two thirds gave just one 
reason for being tested.  
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As discussed above, the majority of respondents who had been tested for BBVs had 
received a battery of all three tests at one time, and gave responses which indicated that 
they thought of the battery as being one test. Even when the tests had been conducted 
individually their reasons for being tested were similar for all three tests, except in the case 
of hepatitis B testing, where an additional reason to be tested, discussed below, was 
mentioned. Therefore, except where indicated, the following description of responses to 
questions about reasons for being tested have not been separated according to virus. 
There were three major categories of reasons for being tested: 
• the respondent had been exposed to risk in some way;  
• it was recommended or required; and/or 
• the respondent was concerned about the possibility of passing on BBVs to others 
A further category, only applicable to hepatitis B testing, was that the respondent had 
experienced signs or symptoms of illness.  
Seventy two respondents (51% of those tested) stated that at least one of their reasons for 
being tested was that they had been exposed to BBV transmission risks. The three sources 
of risk mentioned were unsafe injecting practices, unsafe sex and associating with others 
who were seropositive or engaged in high risk behaviours. Half of these responses related 
to their own unsafe injecting practices. Some of these appeared to be occasional or one-off 
exposures to risk: 
A stuff up - basically I had my own needle - my two friends were sharing one that they were 
going to clean, but my friend gave me one she’d used, so we all ended up sharing, so I 
decided to get tested 
(23 year old woman) 
Others described behaviour which was now, by inference, behind them: 
I’d been using a syringe in jail that everyone had been using and it was put to me when I first 
came on methadone that I should be tested and I did 
(36 year old man) 
Some appeared to be describing more regular practices: 
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Because I had hepatitis B and I’ve been sharing - just to check it out 
(28 year old man) 
Almost a quarter of respondents who had been tested mentioned that having had unsafe sex 
or requiring an examination for sexually transmissible diseases had contributed to their 
decision to be tested.   
I was 18, young and had unprotected sex, and it (HIV) was a really big thing, everyone was 
really paranoid about it. Newspapers make you really scared 
(26 year old man)  
Again, some respondents discussed sexual behaviour in terms of one-off events or 
behaviour from the past. Finally, one in three of those who had been tested mentioned 
being “generally at risk” or (more rarely) being close to others the respondent identified as 
being at risk:  
Because when I found out that my boyfriend was a dealer and a full on user and had been in 
jail for 3 years and been using, I thought “Whoa, shit” because there’s big shortage of 
syringes in jail and thought I’d better get a test done 
(27 year old woman) 
Older respondents were twice as likely as younger (32% vs 15%) to list unsafe injecting as 
a reason for being tested but the reverse was true for sexual risk: younger respondents were 
more than twice as likely to list sexual risk as a factor than older (40% vs 16%).  
Thirty three respondents (23% of those tested) stated that at least one of their reasons for 
being tested was a recommendation or requirement from a doctor, treatment agency or 
prison. Six of the seven respondents who referred to being tested in prison explicitly stated 
that testing was compulsory. For other respondents the degree of coercion involved was 
often less clear. In some instances there was clearly a high degree of coercion involved, as 
when respondents were told that testing was necessary before a treatment or procedure 
would be carried out:  
 It was a requirement - a gastro specified that I do that before an examination, because I 
disclosed I’d injected once “I won’t touch you unless you’ve had a test”. Wasn’t my 
decision, just included in pathology package 
(27 year old man) 
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In other cases the test appeared to be simply the result of a healthcare professional 
encouraging the respondent to be tested:  
Because I went to [local drug treatment agency] and they said that I should get tested and I 
thought I was pregnant and the doctor convinced me to have all these other tests too 
(17 year old woman) 
Even where some degree of coercion seemed to be involved, respondents often indicated 
that they thought it was a good idea: 
It was a policy at the rehab and I thought it was a good idea to get everything checked out 
(37 year old woman) 
Older respondents and those who had been in drug treatment were more likely to indicate 
that testing had been required or recommended than younger respondents and those who 
had never been in treatment. Those who were seropositive for at least one BBV were 
twice as likely to mention a recommendation or requirement as a causative factor in being 
tested as those who were not known to be seropositive. In some of these cases, however, 
serostatus did not influence the recommendation as it was established at the test in 
question. Almost 20% of respondents who had been tested suggested that it was the 
possibility of infecting another person that prompted a test. Slightly more than half of 
these mentioned this concern in connection with a relationship and/or with an intention to 
have children in the future: 
I’d been injecting a little while and had just started a new relationship. We thought it was a 
good idea to be tested before we had sex without condoms  
(20 year old man) 
As noted above, 66% of those tested gave only one reason for being tested, while the 
remaining 34% gave more than one reason. The following diagram shows where overlaps 
occurred. 
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Figure 4: Relationships between reasons for being tested: IDU respondents  
(n = 138)  
Figure 4 shows that the overwhelming reason for being tested was that the respondent 
believed that s/he had been exposed to risk, but that other reasons were important too.  
The same themes as those identified as reasons for being tested for hepatitis C and 
HIV/AIDS were also identified as reasons for being tested for hepatitis B. However, an 
additional theme was also noted. Six percent of those who had been tested for hepatitis B 
indicated that the reason for their test was that they had symptoms of the virus: 
Because I was yellow and not feeling too good, and mates had it, so I got checked 
(28 year old man) 
Bad pain in my stomach, couldn’t hardly walk, was sleeping a lot, skin was yellow (thought I 
had a good suntan) and eyes were yellow. My boyfriend and I used to share needles - he was 
a carrier 
(37 year old woman) 
Reasons for Not Being Tested 
Fifty eight respondents (20%) had never been tested for any of the BBVs under study and 
eight had been tested for fewer than all three (Figure 5).  
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Figure 5:  Interactions between non-testing for BBVs 
Figure 5 shows that most non-testing related to all three viruses. It should be noted 
however, that some respondents who had been tested in batteries were not certain about all 
the tests that might have been undertaken.  
Those who reported that they had never been tested for one or more of the BBVs under 
study were asked why not. Answers given to these questions did not appear to be 
differentiated across BBVs, except in the case of hepatitis B where there was a specific 
additional reason which is described below.  
Almost half of those who said they had not been tested for a given BBV gave multiple 
reasons for not having done so. These answers fell into four broad categories:  
• Respondents believed that they were not at risk 
• Respondents had not “got around to it”  
• Respondents were scared or nervous about test outcomes 
• (For hepatitis B only) respondents had not heard of the test 
Forty three respondents (72% of those who had not been tested) indicated that they did not 
feel a test was necessary or that they did not consider themselves at risk of contracting the 
virus in question. The three reasons people gave for this belief were that they practiced 
safe injecting, that they practiced safe sex and/or that they were simply “not at risk”.  
January 2000 National Drug Research Institute 
Drawing Blood                                                                                                                                                            25 
I’ve thought about it, but never gotten around to it. I really don’t think I’d have anything like 
HIV or the heps because I’m so careful about injecting - I use a new fit every time and clean 
equipment. It’s unnecessary to share anything when you can get stuff so easily from the 
[needle exchange] van and chemists and [local fixed site needle exchange] etc.  
(18 year old woman) 
Forty respondents (67%) indicated that they had not got around to it or were “just lazy”.  
Bit lazy. I go into doctors to get them and they give me referrals to … and I never get around 
to going and doing them.  
(21 year old man) 
These 40 respondents included individuals who made comments to the effect that they had 
“considered being tested” but who gave no further reason for not being tested, and also 
includes two individuals who said they were not sure why they hadn’t been tested. 
Eight respondents (13%) indicated that they had not been tested because they reluctant or 
scared to know their serostatus: 
I knew you’d ask me that, God, well to be honest, I’ve been a bit frightened, you see, I 
stopped using all drugs over 10 months ago, like at the beginning of last year, and when I 
was using I was pretty careful usually, you know, “new fit every hit”, and all the rest, but I 
did have a few slips over the years so I really should be tested 
(20 year old man) 
None of these 8 respondents gave “being scared” as a sole reason for not being tested. All, 
like the respondent above, gave more than one reason.  
Figure 6 shows the relationships between different categories of reason given for not being 
tested for any or all of the three BBVs. 
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Figure 6: Relationships between reasons for not being tested: IDU respondents  
(n = 60) 
Figure 6 shows, again, the importance of multiple reasons and particularly, the overlap for 
considering oneself “safe” but also “lazy”.  
The reasons for not being tested for hepatitis B were similar to those described for hepatitis 
C and HIV/AIDS but an additional theme, ignorance of the virus and/or the test for the 
virus, was also identified. Six respondents either did not know what the hepatitis B virus 
was or did not know that a test for it was available: 
I wouldn’t have thought about it apart from in any relation to a general illness. I haven’t 
been tested for measles either, like that sort of thing. I don’t really know much about it 
(21 year old woman) 
All respondents, regardless of whether they had ever been tested for a given BBV, were 
asked “Have you ever refused to be tested for [the BBV in question] when it has been 
recommended?”. Only 4 respondents reported that they had at some point refused a test 
and they each gave different reasons for refusing:  
Yes, here [drug treatment agency] they used to throw them on you "no methadone" etc., I said 
no because I didn't have the time. 
(47 year old man) 
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I refused a test here [drug treatment agency], wasn't ready for it, I'd been using with junkies 
over from Sydney, everyone rooting each other and shooting up, bad situation, felt strongly I 
was at risk and didn't want to have it. Did go later though. 
(26 year old man) 
Yes, in a job situation - my boss said I'd have to have monthly blood tests to see if I was using 
drugs - by a private doctor – at [a private massage parlour] 
(19 year old woman) 
Yes, only once and that was 26 years ago. I was in jail in Adelaide (medieval days) [they] 
offered prisoners pack of cigarettes if submitted to blood test for STDs and on principle alone 
I refused it. 
(46 year old man) 
All of these individuals also stated that they had at some point been tested for the BBV in 
question, either prior to and/or since the time they refused testing. 
Only 4 respondents reported that they had even been refused a test, and there were only 
two descriptions of this:  
Yes, it was an older doctor in the suburbs and I basically got the "filthy junkie trash" attitude 
"you'll have to go off and pay for them yourself at the pathology centre".  
 (23 year old woman) 
Yes, that was the very first time I went for testing and the doctor laughed at me.  
 (38 year old man) 
The Decision to Test – SP Informants 
SP informants were asked about the circumstances in which BBV testing was or was not 
ordered. For the most part, their IDU clients were offered testing if they had disclosed past 
or current injecting drug use during history taking, and/or if they self-referred for testing. 
Less frequent circumstances were client disclosures of sharing injecting equipment or 
unsafe sex, and referrals from other agencies. A few SP informants (particularly those 
who worked in methadone clinics), said they tested IDUs routinely and some said clients 
were tested if there were symptoms present, an abnormal liver function test (LFT) was 
detected, or as part of an STD screen. 
The majority of SP informants believed that IDUs requested testing because they knew 
someone who was, or had recently been diagnosed, positive. One in three stated that IDUs 
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were well educated and aware of the risks, and a similar number believed that IDUs 
requested testing after some media publicity or health education about BBVs. Other 
perceived reasons for requesting testing included IDUs’ concern about symptoms, a desire 
to give up drug use, and/or make lifestyle changes and concerns about transmission of 
BBVs to significant others.  
Over a third of SP informants said they would re-test a client every time a test was 
requested: this often related to the perception that risk behaviour was continuing as in the 
following:  
Some people come every three to six months and hide the fact that they're continuing to use 
unsafe practises.  
The majority of SP informants, however, said they questioned why re-testing was being 
requested; whether any further risky behaviour had occurred; and/or whether client had 
doubts about previous results or were obsessional. Most said they would re-test if there 
was a valid reason. In fact, a majority said they had never refused to give a BBV test when 
it was requested by them. As one put it:  
If they ask for it there is some worrying reason. I allay their worry and guilt and get it done, 
then use the results as a counselling point.  
Another said, "sometimes it's a waste of time, but we never refuse". Those that had refused 
testing had usually done so because of a perceived inability of the client to give informed 
consent, whether from intoxication or mental instability, at that time. Some said they 
refused to test if they were concerned about client self-harm, for example in response to 
statements like "I'll throw myself off a building if I'm positive." Some said they refused 
because the client had been recently tested and was still in the window period, or were 
what they termed "chronic" or "obsessive" testers. One said they regularly pointed out to 
clients that "testing does not offer protection". 
There was a wide variation in the range of responses to the question about when to re-test, 
but most SP informants said that it depended on the risk behaviour of the client. The most 
prevalent re-test frequency was every 3-6 months, but some reported preferring to test once 
a year.  
Some SP informants said that they accepted that:  
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"Some people's sole safe practise consists of getting re-tested every three months"  
Almost two thirds of SP informants said they had had clients refuse a BBV test after being 
advised to have one. Some said that when clients refused a test they would explain the 
importance of knowing their BBV status in terms of prevention and management. As one 
remarked, "the devil you know is the devil you can deal with". Some said they provided 
refusers with information on risks and harm minimisation. A few said they invited refusers 
back later, or brought it up from time to time as part of ongoing clinical management. 
Most said it was the client's decision. The reasons clients gave for refusing testing were 
that they didn't feel ready to know their status, or didn't want to find out at all. A few SP 
informants said clients wanted to think about it, or go to their own GP (if at an agency) for 
testing. Some said clients did not think they were at risk, were scared of the blood test 
itself or had been tested previously. 
THE TEST PROCESS 
IDU respondents were asked to given details of the most recent occasion on which they 
had been tested for each virus. These descriptions are outlined in this section, with each 
major theme followed, where available, by relevant comments from SP informants.  
One hundred and fifty testing events were described by IDU respondents . Of these, 119 
(79%) were descriptions of batteries of all three tests. The remainder were 31 descriptions 
by 22 respondents of one or two tests conducted on a single occasion. In describing these 
events, only 17% of respondents was describing to a first test experience. For many, the 
experience was routine. Comments along these lines included:  
I just had to have a blood test, I didn’t even get the results, they’re just in my file, if I had 
anything they’d tell me 
(31 year old woman) 
Very routine, went in, took blood, got results, no surprises 
(35 year old man) 
I’d given up using … because of that I suppose, just standard - get checked for everything - 
had quite a few done 
(38 year old woman) 
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Went in, did a test and that was it, never thought much of it 
(27 year old man) 
Even for those having a first test the experience could be uneventful:  
I just had blood tests that took a long time, it was fine 
(22 year old woman) 
Sixty three percent of these testing events occurred at the individual’s request: a further 
14% were recommended by their service provider, and 7% occurred as a requirement 
before entering treatment. A small group of respondents reported that their most recent 
tests were compulsory for other reasons: in hospitals, detention centres, because the 
respondent was a sex worker or as part of a pregnancy check.  
Preparation for Testing 
Three quarters of IDU respondents claimed to have received no pre test counselling 
although some said that this was because they did not want or need it:  
No, not really - had enough knowledge myself - knew it’s a killer and that’s all I have to 
know to want to find out if I’ve got it or not 
(19 year old man) 
No because I said don’t worry about it. Don’t think I really need it - I’ve had it before 
(31 year old woman) 
No, don’t need it. Have been through all that before 
(35 year old man)  
However, it is clear that some respondents misunderstood the question “were you offered 
any pre-test counselling?” apparently believing that this asked whether they were referred 
to another person or agency for counselling prior to being tested:  
No, if I'd asked they probably could have arranged something 
(27 year old man) 
Pretty sure they asked me questions about my knowledge and gave me the option of having 
counselling 
(28 year old woman)  
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Offered. I said no it's better to find out first and then get counselling 
(32 year old woman)  
Of those who underwent pre-test counselling, a few described it in very positive terms:  
Yes - all the info and emotional support, possible outcomes of the test. All round it was a 
good experience really very positive. Resulted in me feeling that even if I was positive it 
wasn't a disaster or the end of the world. He told me - don't take too many tablets, don't 
drink much, you've got to be careful. He's a good doctor 
(27 year old woman)  
But for some, even though the counselling was thorough, the experience might have been a 
waste of time:  
Yes, 20 minutes - I think just explaining what it was and how transmitted. I think they said 
some positive things like if you are positive can live OK and survive quite positively. But I 
was sure I was OK so didn’t pay much attention 
(28 year old man)  
And for others the experience was far from positive:  
Just told me all about hep B and C and stuff, he didn't say what to expect if they came up 
positive. I wouldn't know what to do - probably kill myself 
(17 year old woman) 
Pre-test counselling seemed to have been generally focussed on all three viruses and tests, 
which was presumably because most testing was in batteries: 
Yes, what tests were, what HIV, Hep B and C were, how transmitted and meaning of a 
positive result, what I’d do if I was positive etc 
(28 year old man) 
Whether or not respondents received pre-test counselling was related to the nature of the 
service provider who ordered the test. There was a significant difference (p < .005) in the 
provision of pre-test counselling, with GPs and hospitals being reported as less likely to 
have provided counselling than medical, sexual health and drug treatment clinics. All SP 
informants said that pre- and post-test counselling was provided for a BBV test. This was 
usually carried out by doctors, nurses, counsellors or social workers. In most cases, the 
person who took the blood did the counselling, although a few agencies sent their clients to 
pathology laboratories for phlebotomy. About half of the SP informants said the time spent 
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on counselling varied enormously and depended on factors such as the level of knowledge 
of the client, whether they had or had not been tested before, their background and 
circumstances, risk factors, their needs at the time, and the test outcome. This variety is 
illustrated by the following comments from SP informants who were asked how long they 
spent on test counselling:  
Depends, rarely less then half an hour, can be up to three or four hours. About half an hour 
for pre- and if HIV positive, will spend about 20 minutes on post. It's an opportunistic 
environment, if they engage well we'll make the most of it. Not as much time as we should. 
The majority of SP informants reported using pre-test counselling to assess the client’s 
risk, discuss transmission and prevention, give information about the viruses, tests and 
window period, and establish what clients would do if they received a positive result. 
About a third discussed follow-up testing, treatment and the social impact of results. 
Twelve (31%) informants specifically mentioned that they informed clients about the 
notifiability of results, confidentiality, referral and/or that results could only be given in 
person. The level of client's understanding was also ascertained by some. Disease 
progression, emotional impact and support networks, sexual and drug use histories, effect 
on lifestyle, and issues of disclosure, insurance, employment and legal obligations were 
also mentioned. A few said they encouraged clients to ask questions, provided them with 
written information and discussed false positives and negatives, coding of pathology 
forms, re-testing and/or whether the client knew of anyone with these viruses. Very few 
said they mentioned hepatitis B vaccination at that time.  
The pre-test counselling practice of one SP informant, however, had changed with 
experience:  
I used to spend hours discussing every little thing [but] there's a limit to which they can 
assimilate information; the more you give them, there is a rapid and exponential drop off in 
the value of information … 
Less than one in three of IDU respondents could recall that they had both confidentiality 
provisions and the notifiability of positive results explained to them, but even fewer were 
definite that neither had been explained. In many cases they could not remember. Some, 
however, were sceptical about confidentiality:  
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If I was HIV positive would the doctor have to tell anyone? Is it just a statistic or my name? 
So they'd know who I was ... they already know far too much ... 
(33 year old woman)  
Don’t know how far confidentiality would stretch  
 (28 year old woman)  
IDU respondents said they had given informed consent for the test on almost 80% of 
occasions, although it is not clear in every case what this involved. A minority said they 
had signed a consent form. The remainder could not recall or apparently did not consent, 
as in the case of the following respondent who was tested in hospital:  
They just said they were going to blood test you for everything and that's it, for the safety of 
the other patients too  
(18 year old woman)  
SP informants were asked how they ensured that clients gave informed consent for BBV 
testing. A majority said they explained the significance and meaning of tests verbally, 
often as part of pre-test counselling, and obtained verbal consent, and a few also used a 
formal checklist which was signed by clients. A few gave their clients literature on testing 
to aid informed consent. 
Follow-up to Testing 
IDU respondents reported that they had received their test result in a face to face interview 
with their test service provider on almost three quarters of occasions. However, on around 
one in ten occasions they had received them by telephone, although in one case a 
distinction was made according to test:  
I got phoned for all of them except HIV - had to go into doctor 
(17 year old woman) 
A few also received their results in some other way, such as the following:  
The receptionist opened the file on the table in doctor’s office and HIV positive was 
highlighted 
(30 year old woman) 
My mum called the doctor because she's friends with him and he told her 
(22 year old woman) 
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Went into practice, secretary looked through files and handed me a form, [I]walked out the 
door, opened it and it said negative 
(27 year old man) 
Some respondents had not collected their results. A few of these were waiting for results 
from very recent tests, and most of the remainder believed that they would be informed if 
their results were positive:  
Just didn’t bother, if you’ve got it they’ll tell you 
(38 year old woman tested at drug treatment clinic)  
They didn't give me the results, they didn't come in and tell me I had something [so I] assume 
I don't 
(18 year old woman, tested in hospital) 
You don’t get results unless you’ve got something - they told me that when I asked for results. 
If I had something they would have segregated you straight away. That’s how you know - 
they segregate everyone HIV and Hep into infirmary block 
(22 year old man tested in prison) 
 Forgetting or not being bothered to collect results as in the following was rare: I haven’t, 
I’ve been meaning to go in there the next couple of days, but I’m quite confident 
(21 year old man).  
The majority (82%) of SP informants reported that they always gave BBV results face to 
face during a follow-up appointment, but a few reported that they were less stringent about 
hepatitis C and B results than with HIV/AIDS results, and were prepared to give these over 
the phone. One reported giving hepatitis B and C negative – but not positive – results over 
the phone. They estimated that an average of 91% of their clients collected their test 
results. Approximately half said they would write to or telephone clients with positive 
results who did not return, but would do nothing about uncollected negative results. One 
in three attempted to contact clients who did not return, whatever the result. A number 
commented that it was often difficult to contact some clients, especially travellers or 
transients. 
SP informants’ main explanation for IDUs’ failure to collect results was that they were 
transient and mobile; one in three said that IDUs did not want to know, were fearful of 
results or simply forgot to collect results; some thought that test results were not a priority 
for some IDUs or that they did not care; and others said that IDUs assumed that SPs would 
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call if there was something wrong, even when the contrary was explicitly explained. Some 
believed that failure to collect results was due to disorganised chaotic lives, although 
others explicitly disagreed with this view. Other perceived influences on non-collection of 
results were poor rapport with the testing doctor, life circumstances such as going to 
prison, being intoxicated at the time of testing, or having compulsory tests.  
IDU respondents reported that no post-test counselling was given on 81% of described test 
occasions. There were no SP differences in this, but whether or not post-test counselling 
was received was related to the test result. Specifically, clients who received post-test 
counselling were more likely to be seropositive for at least one test than clients who were 














Figure 7: Post test counselling by test outcome: most recent testing occasions  
(n = 146) 
It should, however, be noted that post-test counselling was said to have been received on 
only 30% of test events resulting in at least one positive result, as shown in Figure 8: 
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Figure 8: Test outcome by post-test counselling: most recent testing occasions  
(n = 146) 
IDU respondents tended to be supportive of the view that  the major role of post-test 
counselling was to follow up positive results. When they were asked whether they had 
been offered received post-test counselling, they made comments such as the following:  
Not really because it was negative. If it was positive I would've definitely 
(33 year old man) 
Because it came back negative I didn’t need any. They did say that it was available 
(34 year old man)  
No but if you had it I think she [the doctor] would’ve  
(37 year old woman)  
Many of those who described post-test counselling, moreover, reported it in terms of 
medical advice given if they were hepatitis C positive:  
I suppose I was given some counselling by the doctor who knew about my situation, more 
along the lines of advice on how to contain and preserve my liver - stop drinking, things I 
already knew about  
(27 year old man)  
January 2000 National Drug Research Institute 
Drawing Blood                                                                                                                                                            37 
Not for HIV, but for hep C. I came up positive which was a bit of a shock. Talked about 
what it meant, what it would do, lifestyle and treatment and stuff 
(31 year old man)  
Only four respondents described post test counselling which was focussed on prevention:  
She just explained the results and suggested I use condoms and keep injecting safely 
(19 year old woman)  
Gave a lecture about using safely - but there should be more information on when and where 
you can get needles - in all areas and at all times of night … 
(19 year old woman)  
Most IDU respondents (71% of occasions) did not take written information away with 
them from the test. In most cases it was not offered or available, but some felt the 
information was superfluous or unnecessary:  
Had pamphlets there, but didn't take any, have pretty good knowledge 
(26 year old woman)  
Yes - pamphlets - can't remember. Threw them away, didn't really read them. If I want to 
find something out I just ask somebody 
(17 year old man)  
She offered me some pamphlets to read, but I didn't think I needed them after she explained 
everything so well 
(19 year old woman)  
On some occasions, however, written material was very much appreciated:  
Yes - with pre-test - HIV, all heps, and I think things to do with legal rights and 
confidentiality issues. Everything was covered, he was such a fantastic doctor 
(27 year old woman)  
IDU respondents reported that they were referred to other medical or community agencies 
on only nine test occasions: of these, seven were occasions where at least one result was 
positive (six hepatitis C, one HIV/AIDS, one hepatitis C and HIV/AIDS). Most of these 
positive clients were referred to specialist medical services, although two were referred to 
the Hepatitis C Council of WA. Two respondents who were negative were referred: one to 
a youth health clinic and one to a clinic for hepatitis B vaccination. Perhaps because of 
this low rate of referral, most IDU respondents said they did not know at the time about 
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local community-based support agencies such as the Hepatitis C Council or the WA AIDS 
Council.  
Almost all (90%) SP informants said they used post-test counselling to discuss prevention 
with clients whose results were negative. About two thirds talked to clients about the 
window period and the possibility of a need for re-testing. Some discussed what a 
negative result meant. Around 20% told clients how lucky they were considering their risk 
behaviours, congratulated them on being negative and encouraged them to continue to stay 
so. One said clients were told that it was not appropriate to continue being tested if they 
continued with risk behaviours. A few offered hepatitis B vaccination to negative clients 
at that time. A few offered virtually no post-test counselling after a negative result. 
With positive results (predominantly hepatitis C) most SP informants used post-test 
counselling to suggest follow-up and monitoring, including further testing (liver function 
test, PCR testing, liver biopsy) and referral to specialists. The majority also discussed 
transmission and prevention issues, including not sharing injecting equipment, razors or 
toothbrushes, and cleaning up blood spills. About half said that in the first session after a 
positive diagnosis they dealt with the client’s shock and other emotional reactions, allowed 
time for them to digest information and made sure that clients understood the implications 
of a positive result. Treatment options as well as possible sources of support were also 
discussed. Other topics mentioned were lifestyle issues such alcohol and drug use, diet, 
exercise and learning to live with the virus, and disclosure issues about the infection. A 
few SPs reported encouraging clients to ask questions, some gave written information and 
a few said they tried to focus on the positive aspects of the result. Combinations of these 
themes demonstrated that there was considerable variety in post-test counselling with 
positive clients.  
Almost all SP informants said they made written information and resources available to 
clients who wanted them. These ranged from government publications, information from 
Hepatitis C Councils, pamphlets from the Gastroenterological Institute, other pamphlets 
and handouts and referral information. Some said they had a wide range of information on 
all BBVs available in their waiting rooms but not specifically handed to clients. A few 
said they had up to date information on HIV/AIDS and hepatitis C, but their hepatitis B 
information was outdated. A number said they were more likely to give written 
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information if the client tested positive. There were some negative views about the 
provision of written information, however, including the concern that clients would be 
overloaded, as in the following comment:  
I don't routinely give out literature, people don't want to walk out with a bundle of stuff  
Other concerns were that literature should not replace discussion:  
.. people don't read pamphlets. I like to encourage them to talk about any issues. People 
have specific needs and it's more important to talk to them about everything.  
Several SP informants said whether they gave out written material or not was dependent on 
the client's needs as well as their literacy, knowledge, capacity to cope and curiosity.  
The majority of SP informants said that they referred their BBV positive clients to 
specialists (consultants, physicians, gastroenterologists), with approximately half saying 
they referred to hospitals. Referral was generally for medical reasons related to hepatitis 
C. About a third mentioned referring to alcohol and drug services and sexual health 
clinics, and a similar number said they referred clients to support services, with counselling 
and Hepatitis C Councils receiving the most mentions. A few said they referred clients 
whenever they felt they could not meet their needs or requests. 
IDU respondents were asked about their cognitions and emotions about the test process. 
They reported that on just over half of the described test occasions they were not bothered, 
worried or anxious. In some cases this was because of a perception that they had not 
practiced unsafe behaviour, and so had nothing to worry about:  
Wasn't worried, didn't really know what was going on, but I knew I didn't have any of those 
diseases  
(19 yr old man) 
For some the test process was routine, but one felt that because he was powerless there was 
no point in worrying:  
Nothing - I’m just used to it now. I’ve done a few years jail, home detention, work release, 
all these different things so I’m used to being shunted around and shown nothing. I just let it 
go, if you let it get to you you’ll end up a screaming mess 
(42 year old man)  
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Other themes included fatalism: when asked what he was thinking or feeling about being 
tested, this man said:  
That it’s a pain in the butt, mainly, just it’s a waste of time. You’re gonna die sooner or 
later, that’s why people do drugs, depends if you want to burn out or fade away... 
(26 year old man) 
Some just hoped that they would be alright:  
Just that I hope it comes back negative, wasn’t really worried, better to be safe than sorry 
(38 year old woman) 
On almost 40% of occasions, however, respondents experienced some anxiety. This 
tended to be related to waiting for results:  
Waiting for the results I was scared just in case anything did come up - devastate family and 
girlfriend. Worried for myself and all the people that are close to me 
(19 year old man)  
Others were concerned because they knew that they had practised unsafe behaviour:  
Had a slight reservation that either of us could have HIV or hepatitis C (not hepatitis B) – 
partner’s history of bizarre and casual sex encounters, possible for HIV. Was quite scared 
actually, even though there was no evidence that we had anything. So easy to catch, 
everyone can get it 
(26 year old man)  
And one found the process intimidating:  
I was pretty nervous actually. I was scared about asking for the test I thought she'd [the 
doctor] think I was a slut and a junkie, but she was so nice and understanding. That calmed 
me down, but it was nerve wracking waiting so long for the results 
(19 year old woman – first test) 
Some respondents were very anxious indeed: 
When I found out this person I had shared with had hep C I started to really worry. It was 
scary waiting for the results - I was pretty anxious. I knew I didn't have to worry about HIV, 
but thought for sure I'd have hep C. I'd heard how contagious it was. I was right. 
(34 year old man) 
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I was pretty worried actually - I’ve done some stupid things in the past like sharing when I’m 
desperate and that and unsafe sex, so I was really rapt when the results came back all 
negative! I thought I might at least have hep C, but I got away with nothing. I was surprised 
and pleased 
(28 year old man) 
IDU respondents complained about the treatment they had received in relation to only 8% 
of testing occasions. Most of these complaints were about the perceived attitudes of SPs 
towards drug users: 
The doctor was pretty good but the fact that he knew I was a heroin user - was pretty firm 
and rude the first time 
(19 year old man) 
On the other hand, a few respondents thought they were treated really well: 
I was given opportunity, support and everything else 
(29 year old woman) 
Finally, respondents were asked to describe any other memorable test incidents. There 
were 32 such descriptions. For the most part the descriptions were negative, and many 
related to the respondent’s perception that they were not given adequate information. For 
example: 
No pre-test/post-test counselling. Wait - even if you've heard it again and again, should 
mention risks and what to avoid to not get viruses and also how regularly to be tested and 
places to go if you think you've been in contact with viruses to get tested again 
(23 year old woman) 
 Others felt they had received inadequate support:  
If I was negative for everything I would expect him to recommend more testing in three 
months. If I was positive I would expect a referral to the Hepatitis C Council and ways of 
dealing with it, referring me to people who can help me mentally and physically  
(19 year old woman) 
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I think it's really vitally important for a doctor to determine exactly what the clients' past is. 
Just because I say I've had tests before doesn't mean I'm gonna handle it alright and I just 
dunno I think it's very important, I think that post counselling as well is really important, 
even if you're negative, I remember being asked what I'd do if I were positive and that made 
me stop and think, made it more real, sent me away with a much more profound attitude 
(27 year old woman) 
But some had experienced shifts in professionals’ attitudes over time: 
I find doctors more understanding these days than what they were 15 years ago - more seem 
to know more and are a lot more friendly 
(33 year old man) 
Respondents were asked “Tell me how you felt when you found out your last test result?” 
The majority of those whose results were negative said that they were pleased, relieved, or 
not surprised. For example:  
I don’t know how to describe it, I guess I did one of those Toyota commercials - jumped up in 
the air “Yay!”, rapt 
(27 year old man) 
Very very relieved because I was worried to death 
(36 year old man) 
Those who received positive test results (almost entirely hepatitis C) were almost equally 
divided between a range of responses: being upset/angry/concerned; not surprised; 
focusing on their state of illness or health; feeling positive about their diagnosis or 
describing being upset at first, but coming to terms with the diagnosis over time.  
For example:  
When I first found out I was positive I was horrified, couldn't believe it, broke down, didn't 
think that I'd have it. I hadn't been using around that time, I'd just had a baby and was 
breast feeding. It was devastating. I felt like I was used as a guinea pig 
(31 year old woman) 
The first time I was told I was positive I was not really surprised because of the situation - I 
had put myself in a situation where other people were positive, so I wasn't really surprised, 
but kind of a bit anxious 
(25 year old woman) 
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It hadn't got any worse - liver count was up but probably due to drinking than to hepatitis C. 
When I found out I was positive it was a big shock, because I'm omnipotent, I don't get sick, 
or old … 
(33 year old woman) 
Positive - I suppose I was still a bit nervous but I felt it was all quite manageable with the 
counselling that was offered with it. A very thorough doctor 
(27 year old woman) 
I felt you know “death sentence” almost like I had AIDS really, because there’s no cure for 
it. But the doctor did say that some people, their bodies do get rid of it and look after it, at 
first it was dismal, but when doctor explained that I’m not a chronic carrier, OK 
(32 year old man) 
SP informants were asked what range of emotions they saw in relation to BBV testing and 
how they dealt with these. They described a wide range of emotions, but anxiety received 
the most mentions, followed by acceptance, resignation, anger and fear. Relief over a 
negative result was also common, as was concern for others (partners, children), surprise, 
and grief. Other groups of related emotions included disbelief, shock, panic, hysteria and 
obsessing; apprehension, stress, frustration and angst; distress, despair, dismay, devastation 
and blame; disgust, dirtiness, regret, remorse, guilt, disappointment, sadness and denial. 
There were also reports of some clients being blasé, nonchalant, calm, indifferent, 
apathetic or complacent, while others reacted with bravado, curiosity or interest. A few 
said clients asked “why me?" or said "I deserve it". Some SPs said the strongest reactions 
they got were from people who had not injected for years and returned positive results.  
Most dealt with these reactions with counselling. A third said they provided more 
information and some said they referred clients on. Some said they offered support and 
spoke of the importance of active listening and allowing plenty of time for the client to 
come to terms with the result. Some tried to normalise the situation by letting clients know 
their reactions weren't unusual. A few said they tried to give patients hope with facts about 
the viruses. One GP admitted to not dealing with these issues very well:  
I deal with them probably pretty badly. I don't think I deal well with IDUs, I think I deal with 
them mechanistically and can tend to be a bit guarded.  
One service provider said:  
 Sometimes I'm as relieved, surprised and anxious as they are 
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THE CONSEQUENCES OF TESTING 
Many of the reasons given by IDUs for being tested were consistent with the types of 
response test-seeking respondents would have given to a doctor or clinician to explain their 
desire to be tested. Such responses, while of value in their own right, offer limited insight 
into the relationship between the testing process and the respondent’s behaviour. With the 
possible exception of those who stated they sought testing in connection with a 
relationship, the reasons given for seeking testing did not indicate how respondents used 
the information gained through the testing process.  
A series of questions sought to explore this relationship between test results and the 
subsequent behaviour of respondents. These questions addressed the respondent’s reaction 
to the test results, the impact of the respondent’s positive or negative serostatus on their 
life, and changes to behaviour following the test. 
This section is divided into three parts. The first section discusses the impact of negative 
results, the second section discusses the impact of positive results and the third section 
discusses changes to behaviour following testing, regardless of the results. 
Negative Results 
Every respondent who had received a negative test result was asked: “Tell me how you felt 
when you found out your last [BBV in question] test result” and “What effect does your 
negative serostatus have on your life?” In most cases the responses to these questions were 
not differentiated by the virus concerned. Responses to the two questions about reaction to 
negative test results have therefore been grouped except where indicated. 
One hundred and thirty nine respondents described how they felt about being negative for 
one or more BBVs, with many giving more than one response. 
The majority indicated that they were relieved about the result, even if they had been 
expecting it: 
Relieved in a way even though I was sure I was clean 
(18 year old woman) 
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This relief was sometimes expressed in a quite judgemental manner: 
Just relived, very relieved. Gave me a feeling, a sense of cleanliness. Felt clean, not like 
"junkie scum" You see some people around with no respect for themselves 
(19 year old man) 
A small number added that as well as being relieved, they believed that their negative 
result was also a matter of luck and a couple added that as well as being relieved, their 
negative result was an inspiration to be more careful: 
I was really rapt - and very surprised. I’d been too nervous to get tested before, but I was 
glad I had to start the [methadone] program. I really couldn’t believe I was all clear 
considering a few occasions of pretty dodgy behaviour in my past! It’s really motivated me 
to be super careful from now on. 
(28 year old man) 
A few respondents said that as well as being relieved, they believed their negative result 
vindicated their behaviour:  
Relieved and sort of glad with myself as well, knowing I’ve been careful when using, knowing 
I did the right thing, haven’t shared 
(23 year old man) 
Respondents were asked what effect their negative status had on their life, and gave 
multiple responses, again not differentiated by BBVs. Nearly a quarter said discovering 
they were negative had no impact on their lives, and made no further comment. 
Almost half of those who discussed the effect of their negative serostatus took this 
question as a point at which to say how happy they were that they were negative. Some 
said that it was good they were negative and then discussed how they would feel or what it 
would mean if they had been positive: 
Like I said, a lot, as if I was positive I think it would be totally different - I don’t think I’d be 
into drugs, and that’s most of my social life right now 
(22 year old man) 
A few discussed their negative status in terms of what it meant they could do, namely have 
unprotected sex:  
National Drug Research Institute   January 2000  
46                   Drawing Blood  
It's nice to be able to have sex with my partner without having to panic about the safe sex 
thing all the time 
(23 year old woman) 
None, just means can have sex without condoms 
(20 year old man) 
and two people explicitly stated that knowing they were negative made them behave less 
safely: 
Good effect - I wish I was a lot smarter than I am - wish I didn’t share - I’m glad and proud 
and relieved that I don’t have any of these things as positive - don’t you think it’s pathetic 
that I’m one of these people that am happy that I’m negative, but then goes out and shares 
again? I feel so stupid - that’s the reason I get tested, then I’m relieved, but then go out and 
share again. It’s so wrong and I did it. I think my boyfriend would as well, even though we 
made an oath not to. 
(21 year old woman) 
It makes me be less cautious when it comes to matters of transmittable diseases. Reckless. 
It’s the opposite to self-preservation I s’pose. My body’s OK and I can still go out and stuff 
it up anyway - until it’s stuffed up I won’t look after it 
(23 year old man) 
A number of people, on the other hand, felt that their result influenced behaviour in a 
positive manner: 
Because I’m negative I certainly go out of my way to not put myself in a position where I 
could become positive; I don’t share needles with anyone except partner and I don’t use a 
needle that I’m not sure of its history. 
(44 year old man) 
Positive Results 
Every respondent who had received a positive test result was asked “Tell me how you felt 
when you found out your last [BBV in question] test result” and “What effect does your 
positive serostatus have on your life?” Most responses related to hepatitis C with fewer 
discussing hepatitis B, and only 2 discussing HIV.  
Fifty nine respondents described their initial response to finding they were hepatitis C 
positive. Just over 40% said they were not surprised, but in many of these cases the testing 
event being discussed was a follow-up to an earlier positive screening test result, so their 
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lack of surprise was at the confirmation, and in some cases the test event they were 
describing turned out to be a liver function test or similar post-test evaluation.  
A small number said they were unsurprised because their past behaviour was such that 
they expected to be positive: 
I was relieved I didn’t have HIV - I knew I probably didn’t, but you never know, I did some 
pretty wacky stuff in the past. I was really expecting to have hep C, so that was no surprise 
but not very nice nonetheless. 
(36 year old man) 
One in three said they were surprised, upset or angry to find that they were hepatitis C 
positive: 
Fairly devastated really - almost more so than HIV - double whammy 
(36 year old woman)  
Really annoyed, as said before, at the person and at myself for being so stupid and careless 
(37 year old man) 
On at least one occasion the respondent indicated that part of their anger was in connection 
with the way the testing process had been handled: 
I felt angry because it meant that I was probably hepatitis C positive at my second test and I 
wasn’t contacted 
(44 year old man) 
A few respondents indicated they were indifferent to finding they were hepatitis C 
positive, but in at least one case, this appeared to be due to lack of knowledge about 
hepatitis C: 
 Didn’t sort of care because I didn’t have HIV - didn’t know much about hepatitis C 
(31 year old woman) 
In terms of the impact of their positive status on their lives, only a small minority had 
found that being hepatitis C positive had had no effect. Most described the effects in terms 
of other people and/or their own physical and emotional health.  
For some the major impact of their serostatus was the effect of negative or ignorant 
community attitudes towards people with hepatitis C: 
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I .. was babysitting a little girl – she asked for my drink and I said no. Her mum asked why, 
and I told her I had hepatitis C, and she never employed me again. That upset me  
(31 year old woman) 
Many of these respondents discussed the impacts of such attitudes on their relationships: 
[It] was quite a shock to me and contributed to break up of my marriage. Wife didn’t want 
me in the house when I was hepatitis C positive. Didn’t want to have sex any more or 
touching the cutlery. 
(42 year old man) 
Thirty six respondents discussed the direct effects of their serostatus: emotional impacts, 
physical symptoms, the need to alter their diet and drug use, and generally the need to look 
after their health more closely: 
It just makes me feel tired in the afternoons and I have a hard time getting up in the mornings 
(33 year old man) 
I’m very tired a lot and I suffer depression, have to always be on antidepressants. 
(32 year old woman) 
I curb it pretty well with diet and I’m taking antioxidants and vitamin E 
(42 year old man) 
[I have to]watch alcohol and paracetamol consumption 
(30 year old man) 
Gotta stop drinking - Friday night asked to a birthday party with a keg so I didn’t go, so it’s 
affected me socially.  
(19 year old woman) 
Three of these respondents, however, explicitly stated that they did not do the things they 
had been told they should: 
Well I’m conscious of it and conscious of liver damage but I don’t do the recommended 
things like not drink. 
(44 year old man) 
Almost half discussed the impact of their serostatus on their need to consider others, for 
example in relation to transmission issues or on being around (or having) children: 
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I would never lend anyone a syringe of mine or use anyone else’s syringe apart from my sex 
partner, and not if I had one of my own 
(33 year old woman) 
I haven’t been in a relationship for a long time; gotta be really careful especially when I’ve 
got my period and especially with the kids. I’m forever telling them not to touch needles or 
other people bleeding to prevent transmission 
(31 year old woman) 
Ten of the 12 people who indicated they were hepatitis B positive described the effect of 
this on their lives. The majority described themselves as long-term carriers (usually with 
no physical symptoms) who felt “fine” or “nothing” with respect to their most recent test.  
Only two people indicated that their last test had been the one at which they had 
discovered their serostatus. One of these people expressed surprise; the other resignation: 
Surprised really because I've never felt sick 
(37 year old man) 
Other IDUs were coming down with hepatitis B at the time so it wasn’t really a shock, it was 
just one of those things you got 
(31 year old woman) 
In response to the question about the impact of their hepatitis B status on their life, most 
who had been carriers for some time said their status had little effect on their life, and the 
remainder expressed some concern: 
I’ve gotta be more careful, gotta tell people 
(37 year old man) 
None really, I’ve been carrying it that long - if I got in a relationship be morally bound to tell 
them. Been carrying it for over 10 years, been offered to go on interferon treatment, haven’t 
done it yet. Rarely think about it - realise I’ve gotta look after my liver. Having it for so long 
concerns me - liver not functioning properly 
(42 year old man) 
There were only two HIV positive people in the group: both women. One had received her 
result with acceptance, while the other did not state how the test result had affected her. 
Both HIV positive respondents made some comment about the effect on their lives.  
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It’s been very roller-coaster ride - good/bad days. Can’t forget but react in different ways. 
A lot has changed in 10 years - but a lot hasn’t 
(36 year old woman)  
Being celibate, and just making sure that picks and spoons were clean and all that  
(39 year old woman) 
Changes to Behaviour Following Testing 
Respondents who had been tested at least once were asked if they had changed their 
behaviour in any way subsequent to their last test. Those who answered “yes” were then 
asked what these changes were and if they had changed their behaviour back. Those who 
answered “no” were asked why not. 
Figure 9 shows behaviour change by test outcome: that is, whether the respondent was 











Antibody negative (n = 93) Antibody positive  (n = 57) 
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Figure 9:  Behaviour change after most recent testing occasion testing, by test(s) 
outcome (n = 150) 
Figure 9 shows that the majority of respondents, regardless of the test outcome, did not 
change their behaviour after the test.  
In their descriptions of the 150 most recent test events, respondents reported behaviour 
change following just 19% of these events. Almost all described these changes. These 
descriptions have been related to the outcome of the test.  
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Respondents from 57 most recent test occasions had at least one positive result. Twelve 
(21%) of these said they had made some behaviour changes subsequent to the test: five 
towards reducing or stopping drug use; five towards reducing injecting or sexual risk and 
two used more drugs or started to inject. Thus 10 had moved towards safer, and two 
towards less safe behaviour. Some examples of these follow:  
Yes, Don't drink, eat healthily, I'll probably still use heroin and be incredibly careful about it. 
Now that I can't drink, I'm thinking it's the one thing I can do. Only other drug I take is 
Ecstasy.   
(19 year old woman)  
Yes, I didn't put myself at risk - made sure I didn't share spoons, needles, filters, water. I 
didn't know you can catch it from spoons  
(32 year old woman)  
Yes, might have used a bit more ‘cos everything [liver function]was getting better  
(30 year old man) 
Following the 93 test occasions which resulted in only negative results, there were 17 
(18%) behaviour changes: 10 towards less risk, four towards more risk and three towards 
reduced stress or feelings of happiness.  
Yes, just a bit more at ease, a bit more happier probably, 
(42 year old man) 
Of those who reported more risk, two said they were more inclined to have unprotected 
sex:  
Yes, more relaxed, - knowing that I was all clear. Had unprotected sex with partner 
(23 year old woman) 
Yes, started having sex with my girlfriend without condoms.  
(20 year old man) 
One person described changes with mixed or unclear implications for safer use:  
Yes, maybe to check the spoon and cotton were clean - was aware but didn't make a big deal 
about it. On the other hand for a while the idea that I already had hepatitis C made me feel 
less anxious about using someone else with hepatitis C’s syringe. I know you can cross-
infect, but.. ? 
 (27 year old man) 
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Only one person said she had made some behaviour changes then changed back to prior 
behaviour patterns: 
Probably only lasted about a month because I stopped [sex] work and settled back into my 
long term relationship - haven’t had to put them to the test  
(28 year old woman) 
As shown in Figure 9, the majority of tested respondents indicated that they had made no 
changes to their behaviour following their last test. The most common reason given by 
respondents for not changing behaviour was that they were “already safe”:  
No, because obviously the things that I’m doing are pretty safe - just keep using frangers 
[condoms] and make sure I don’t share needles 
(18 year old woman) 
No, because obviously I was maintaining safe practices therefore I shouldn’t try and 
change/lower them in any way 
(23 year old man) 
Eight hepatitis C positive people said they had made no change because they were already 
positive. For half of these the lack of change since the last test was because they had 
discovered their serostatus prior to the last test and had changed their behaviour at this 
point: 
Because I think I got hep C in about the first year of using and in the last 8 I haven’t caught 
anything - I’ve been a hell of a lot more careful 
(31 year old woman) 
whereas others seemed to think of their positive serostatus as meaning they no longer had 
anything to avoid: 
No, because the way I was living my life, I continued to live my life in that way - basically 
knew it would come back positive 
(38 year old woman) 
Some people said they had not changed their behaviour because their result was negative: 
No, not really no - I was pretty sure I didn’t have it to start with and they said I definitely 
didn’t have - just continued on with same behaviours 
(33 year old man )  
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Whereas others said they had made no changes because they no longer used drugs: 
No, had stopped using anyway 
(29 year old woman) 
A few respondents indicated that they had only been tested because of what they felt to be 
one-off or rare aberrations in a context of otherwise safe use: 
Just got test done to make sure because sometimes when you’re out of it things get mixed up 
(33 year old man) 
I wasn’t getting tested because I’d been unclean or irresponsible - my partner had 
(22 year old woman) 
Three people indicated that they had not changed their behaviours despite their 
understanding that their behaviours were high risk and they were currently seronegative: 
I’m pretty much doing the same things that will cause me to get into trouble - sharing etc. 
(21 year old woman) 
HEPATITIS B VACCINATION 
IDU respondents were asked “What do you understand about hepatitis B vaccination?” 
There were a variety of answers. Almost half of the group said that they knew little or 
about it: 
Not much, would I have had it when I was a baby? 
 (21 year old male) 
One in four respondents demonstrated some understanding that hepatitis B 
vaccination helps prevent hepatitis B. This understanding was expressed in a 
variety of ways: 
Given a very small sample of hepatitis B in order that immune system responds by creating 
hepatitis B antibodies, immunising you to future exposure to hepatitis B viral particles 
(27 year old male) 
Just stops you from getting it, doesn’t it? 
(19 year old female) 
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Fifteen percent of respondents provided a response indicating both that they 
understood the concept of immunity/vaccination and that they realised hepatitis B 
vaccination involved a series of injections over time: 
I've been vaccinated. Don't know anything really. I've had my two shots (3 mths and 6 
mths), presume I'm immune to it. Leave it to the medical profession for the rest of it 
(40 year old female) 
Some respondents knew that hepatitis B vaccination involved a series of shots over 
time but did not mention anything about immunity: 
You have 3 shots over a period of so many months and don't have to go back for another for 
5 years or something 
(18 year old male) 
Respondents were asked if they had ever been vaccinated against hepatitis B.  Almost 
60% reported that they had not; 24% said that they had; 9% were hepatitis B positive 
(immune); and 8% were unsure. Two thirds of those who had been tested for hepatitis B 
had not been vaccinated despite the fact that so few were immune.  
Not Being Vaccinated  
There were 119 people who had not been vaccinated against hepatitis B, and one whose 
course was incomplete. All were asked “Why haven't you been vaccinated against 
hepatitis B?” The most common response, given by almost half of this group, was that had 
never heard of vaccination against hepatitis B or did not realise that such a vaccine was 
available: 
Never been offered, never knew it was available until yesterday 
 (23 year old woman) 
Not to my knowledge - I wasn’t aware what the actual virus is, so didn’t realise there’s a 
vaccination 
( 21 year old man) 
Didn’t know there was a vaccination or that hep B had anything to do with injecting drugs 
( 23 year old woman) 
Another frequently occurring theme, related to the above, was that no-one had ever 
suggested they should be vaccinated or offered them the opportunity: 
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I've never asked for one, or been offered one. I suppose I don't think I'd need one 
(28 year old man) 
Some respondents suggested that their reason for not being vaccinated was that they were 
at a low risk of hepatitis B infection and that vaccination was therefore unnecessary: 
I didn’t know you could - suppose I did know but never considered myself at risk, but I have a 
very small understanding of how you contract hepatitis B, gather it’s through blood 
( 19 year old man) 
Just never got around to it, didn't think I was in a high risk category 
( 29 year old woman) 
A number of respondents said they had not got around to being vaccinated although they 
knew it was available:  
Never really been interested, or thought about it that much. I've never been in a place long 
enough to do it. It takes a month doesn't it? 
( 25 year old man) 
I don’t know - I’ve been told to by friends “You should get one because you never know” but 
I never got around to it 
( 21 year old woman) 
And only a few indicated that they were considering it: 
As I said I've only just found out about it. I'd like to find out more about it and if I think it's 
appropriate then I shall do so 
( 31 year old woman) 
A few respondents expressed reluctance to be vaccinated on the grounds that they were 
opposed to immunisation, disliked intra-muscular shots or were reluctant to visit a doctor: 
Don’t like needles! Mainlining’s just a little prick, but into the muscle hurts 
(32 year old man) 
I don't know, - I've done some naturopathy and don't believe in immunisation 
(19 year old woman) 
Five respondents mentioned cost as a contributing factor to the decision not to be 
vaccinated: 
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Started to be [vaccinated] but they didn't tell me that it cost, so they charged me $70 for the 
first shot and test. Couldn't afford it 
(19 year old woman) 
Those who had not been vaccinated were asked how they felt about that. The most 
common response, by more than half, was that they were unperturbed:  
Not really that bothered, I didn’t really feel at risk for it, so it’s not something that really 
keeps me awake at night 
(19 year old man) 
Fine I guess - most people on the streets aren't vaccinated 
(17 year old woman) 
To some, this was related to a belief that they were not at risk of contracting hepatitis B: 
Not too bad ‘cause I don't think I'm a high risk ‘cause I don't use that often and if I do I don't 
always use needles and when I do use needles they're always clean and I'm not living with 
anyone that's got hep C or anything at the moment 
( 22 year old woman) 
Nearly a third, however, said that they would be interested in being vaccinated: 
Maybe I should get one now I know there is one, as I use needles 
(23 year old man) 
Six respondents expressed their disappointment that they had never been informed that 
such a vaccination was available: 
I'm a bit pissed off actually that I've never heard of it. I would have had it 
[vaccination]before now 
(18 year old woman) 
A few respondents were worried because they had not been vaccinated, and two felt that 
vaccination should be readily available and affordable: 
I think it’s a shame that the government won’t put it on Medicare because it’s something 
that’s affecting a lot of people and they should do something about it - I don’t think it’s right 
that people can’t be protected against a disease like that just because they can’t afford it 
( 16 year old woman) 
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Those who had not been vaccinated were asked whether they were more careful because of 
this. The majority said they were not, and almost all of those who said they were said they 
employed safe injecting or sexual practices.  
Sixteen respondents were unable to say whether or not they had been vaccinated and were 
asked why they did not know. There were only two themes in the responses to this 
question: no memory of being vaccinated and/or believing that vaccination may have taken 
place during childhood.  
I don't think so - I don't know much about it. I don't think I have - is it one of those things 
you get at school? 
(21 year old woman) 
I don't know - I might have been at school or when I was a baby? No one’s ever directly 
mentioned it to me 
(17 year old man) 
I may have been but I don’t know - haven’t had vaccination for anything, last I can remember 
is tetanus - don’t go to doctors much 
(37 year old man) 
Being Vaccinated  
The 48 vaccinated respondents had been vaccinated between 0 and 190 (median 32) 
months previously. A quarter had been vaccinated within the previous year and almost 
half within the previous two years. One in five had been vaccinated more than five years 
previously. Two thirds had received three injections; 14% had received two injections and 
5 said they had received a booster shot some time after the course of vaccination. Twenty 
percent said they had been tested after the course of vaccination to check the level of 
immunity. Sixteen percent said they had been tested before commencing vaccination. 
Three people said they had not had any blood tests and one person could not remember 
whether they had been tested. The median length of time for the entire course was 5 – 6 
months. Most respondents (86%) did not have to pay for their vaccination; the reported 
cost from those who did pay varied between $40 and $70 for a full vaccination, or between 
$12 and $25 per injection.  
The most common reason for being vaccinated, mentioned by 45%, was that vaccination 
was suggested by a doctor or clinic staff: 
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At my doctor's recommendation - basically through my drug use. There was a lot about 
hepatitis B that I didn't know and discovered I'd been in a lot of risk situations 
( 23 year old woman) 
When I got my test results back the doctor suggested I have hep B vaccination, I thought it 
was a good idea - better safe than sorry. I’ve just had my last shot about a month ago 
( 28 year old man) 
The second most frequently mentioned reason for being vaccinated was to guard against 
hepatitis B: 
Just started. hepatitis B can be more dangerous than hepatitis C in acute phase and makes 
you more sick and when you’re a drug user - can’t be too careful, got to take all the 
precautions you can. It’s readily available at the clinic and [they] encourage you 
(28 year old woman) 
Around 20% indicated that their decision to be vaccinated was job related: 
Was a policy going through a company I was working for in Qld - part of health and safety 
( 33 year old man) 
Because I was a volunteer at a needle exchange - all volunteers have opportunity to be 
vaccinated - might as well get it for free while I can 
( 21 year old woman) 
While for others, overseas travel plans contributed to the decision to be vaccinated: 
Because it was a service that was offered that didn't cost anything and I was going to travel - 
walking around with bare feet in not so clean countries 
( 23 year old man) 
Vaccinated respondents were asked how they felt about being vaccinated; three quarters of 
those said they felt happy about it, and more than a third suggested that they felt safe from 
contracting hepatitis B: 
Good, at least I know I'm not gonna catch that 
( 38 year old man) 
A few respondents indicated that vaccination was not a bad thing but were not enthusiastic 
about it either: 
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I'm pretty indifferent … , it's handy but I'm not terribly thrilled or upset about it 
( 26 year old woman) 
When asked what difference being vaccinated made to their lives, most said it made little 
or no difference, but one in five said they felt relieved about being vaccinated or that it 
gave them peace of mind: 
It doesn't make any difference except I know peace of mind in my head that it's been done, 
that base has been covered, but whether I'd been vaccinated or not I doubt I would have 
changed any aspect of my lifestyle 
( 27 year old man) 
Almost all (81%) of the vaccinated respondents indicated that they had completed the 
course. The remainder, except for one who was unsure, had not completed.  A few said 
that reminders by their doctor facilitated the completion of the course. One person finished 
the course because he was in prison, while another had his vaccination arranged by his 
employer. 
Half of those who had not finished their course said that they had either forgotten to 
complete it or had not followed it up: 
No, started two times the series but never followed up, so had two needles in two years. But 
have decided never to be exposed to hepatitis B, use safely 
( 31 year old woman) 
The interviewer conducted a short education session on hepatitis B vaccination with each 
respondent at this stage of the interview. Respondents were then asked “Now that you 
know a bit more about vaccination, would you consider being vaccinated?” Most of those 
that had not been vaccinated were open to the idea: they cited protection against catching 
hepatitis B; having an intention to be vaccinated and “seeming like a good idea” as 
reasons. A number of respondents indicated they would consider being vaccinated 
although they did not regard themselves as being at particular risk.  
The education session included the information that IDUs could be vaccinated free of 
charge. This point was raised by 10% of respondents who said they would consider being 
vaccinated: 
National Drug Research Institute   January 2000  
60                   Drawing Blood  
Yes, if it’s for free I might as well get it done. I thought it cost $50 or something - I’m not 
gonna spent $50 on that when I can go and have a hit 
( 21 year old man) 
Having now received information about vaccination was mentioned by some respondents 
who indicated they would consider it: : 
Yes, definitely - I can't believe I haven't heard of it until now. Anything to stop from getting 
these, you know hep B, HIV and hep C. I wish there was a vaccination for all of them 
( 18 year old woman) 
A number of respondents said they would consider vaccination because they believed 
themselves to be at risk of infection, either through their own activities or those of a close 
other and a few said they would also like to speak to their doctor about vaccination. Three 
respondents mentioned that they had hepatitis C and that vaccination against hepatitis B 
could help prevent them from becoming even more sick.  
The twenty-three respondents who said they would not consider vaccination included 15 
who said they were immune, four who said they were not at risk of contracting hepatitis B, 
two people who were opposed to immunisation in general and one who said the needles 
used for vaccination were “too big”.  
SP Informants’ Views on Hepatitis B Vaccination 
SP informants were asked a range of specific questions about vaccination and their 
vaccinated clients. Almost half said that their vaccinated clients were predominantly 
IDUs, a third said they were indigenous Australians and a third that they were 
occupationally related (eg. own staff, health professionals, emergency workers such as 
police, fire brigade, aged carers). Some said anyone who was hepatitis B negative was 
offered vaccination as well as anyone who requested the vaccination, or as one said 
"anyone I can talk into it". Other groups mentioned were gay men, sex workers, sexually 
active youth, Asians, non-English speaking ethnic minorities, the families of those who 
were hepatitis B positive, players of contact sports and travellers. 
All SP informants believed that IDUs needed to be advised to be vaccinated. Half said that 
vaccination came about mainly as a result of their recommendation; almost a third that 
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clients requested it, and some that it was a bit of both (request and recommendation). 
Some thought that hepatitis B vaccination needed to be pushed more:  
I don't think the message about hepatitis B vaccination has got through as much as it might 
to IDUs  
and at least one admitted 
 I think it's a good idea, I haven't been doing vaccinations for hepatitis B  
When asked how they ensured that clients gave informed consent for a vaccination, almost 
three quarters of the SPs said they explained what vaccination was, why it was important, 
the benefits and what was involved as well as side effects. A few gave written 
information, and fewer said they had clients sign a consent form. A few commented that it 
was simply a part of pre- and post-test counselling. 
SP informants were asked how well clients complied with the vaccination regimen. 
Almost half said they experienced close to 100% compliance, while a few suggested that 
clients with an occupational motive for vaccination were more compliant than others. 
Some said clients dropped out after the first or second shot, while a few said they improved 
compliance with an accelerated regime (second injection one week after the first, and the 
third a month later with a booster if required). Almost half used a reminder system where 
clients were sent letters reminding them to come in for subsequent shots. Almost half of 
the SPs had experienced no differences in compliance between IDU clients and others.  
Almost half (48%) of SP informants did not charge for hepatitis B vaccination, and another 
quarter did not charge those at high risk. Among those that charged, prices ranged from 
$7.00 to $30.00 per injection with a mean of $16.00. Almost a third thought this cost was 
difficult for clients, but others commented that the cost was reasonable spaced over the six 
month period. A few believed that hepatitis B vaccination should be universal. 
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DISCUSSION  
This discussion provides a brief commentary on the data using the same headings as were 
used in the data presentation.  
DESCRIPTION OF RESPONDENTS  
The IDUs respondents were similar in many ways to other groups of IDUs that we have 
recruited in Perth, although they were, on average, younger by some 3-4 years than the 
stereotypical IDU found in Australian research. That occurred because of the deliberate 
over-sampling of younger respondents which, although the age quota was not met, affected 
the overall age distribution. The age distribution is also reflected in rates of treatment 
experience, in that only 50% of the group had ever participated in a methadone program. 
The proportion who had injected heroin, compared to the proportion who had injected 
amphetamines in the month prior to interview (67% of heroin users compared to 28% of 
amphetamine users) is an indicator of the popularity of heroin compared to amphetamines 
in Perth at that time.  
Seventy percent of the IDU respondents generally, and almost all of those over the age of 
24, had been tested for all three viruses. This compares well to the ASHIDU data in which 
between 79 and 91% of IDU respondents had been tested for the three BBVs. It also 
demonstrates the ubiquity of testing in this population.  
While it is clear that the SPs were not representative of their population, they were drawn 
from a wide range of services, and from each Australian jurisdiction. They conducted, on 
average 40-50 tests for each virus per month, so were well experienced in testing for BBV. 
It could, therefore, be argued that the method of recruitment maximised the possibility that 
those that were most interested in, and educated about, BBV in IDU would be recruited.  
THE DECISION TO BE TESTED  
The reasons given by SPs and IDUs for suggesting or requesting testing were remarkably 
similar. The SPs referred to at-risk behaviour, requests for testing, routine testing (eg 
when IDUs entered treatment); symptoms of infection and BBV testing as part of STD 
screening. Most, moreover, said they would not refuse to test when this was requested. 
The IDUs’ reasons for testing were that they had engaged in risky behaviour, that they 
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were undergoing screening for STDs, that their medical practitioner had suggested it, or 
that they were required to by their medical practitioner, drug treatment agency or detention 
facility. Importantly, there was a considerable flavour in the IDUs’ responses that the real 
function of testing was to “prove” themselves “clean”: this is attested to by the frequency 
of testing with approximately a quarter of the group being tested between 2 and 4 times a 
year and a quarter being tested annually. The data suggest that IDUs requested testing so 
that they could reassure themselves that they were not a risk to themselves or others, but 
that recognition that their behaviour put them at risk resulted in frequent testing for 
reassurance. In this they were supported by the SPs who were, on the whole, prepared to 
test whenever they were asked. Accounts of the emotional responses to negative test 
results, ranging from relief to exhilaration, bear out these contentions.  
Both data sets suggest that testees and testers acted from an implicit quarantine model. 
Testees wanted to know their status in the assumption that if they found they were positive 
they could self-quarantine: if not the status quo could be maintained. Testers acted within 
a quarantine model by assuming that regular testing was valuable to detect the infected as 
early as possible before they could unknowingly infect others, and that the knowledge they 
were positive would allow the testee to self-quarantine. Whether or not those assumptions 
appear justified in the light of the data about the consequences of testing will be discussed 
at a later point.  
THE TEST PROCESS  
Guidelines for service providers when testing for hepatitis C have been prepared by the 
National Health and Medical Research Council (NHMRC, 1997).4 These, inter alia, lay 
out standards for pre and post test counselling, suggesting that the outcomes of counselling 
should be the provision of psychosocial support, prevention of the transmission of hepatitis 
C and the optimisation of treatment outcomes. Our data suggest that, in the main, only the 
last of these outcomes is being met.  
According to the guidelines, pre-test counselling should: 
                                                 
4 Later guidelines – eg RACGP, 1998 - were not available at the time of data collection.  
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• assess risk 
• provide clinical information 
• enable the patient to decide whether they should be tested 
• provide information about the test and the possible consequences of testing, including 
confidentiality and notifiability 
• provide information on testing benefits 
• establish the ability to give informed consent 
• identify support available to the patient.  
As we have seen, the majority of our tested respondents reported that they received no pre-
test counselling although it is not always clear what they believed was meant by the term. 
Many of them, moreover, said they neither wanted or needed counselling, and this was 
often accompanied by remarks about the routine nature of the test for them, and the fact 
that they had been tested before and did not need all the information again. The notion that 
pre-test counselling should contribute to the decision to be tested was inapplicable in many 
cases when the IDU was requesting the test.  
IDUs’ recollection of whether the confidentiality and notifiability provisions were clearly 
explained was somewhat hazy, suggesting that this was not a high priority for them, and 
only one in three of our SPs mentioned that they explained confidentiality and notifiability 
although whether this related to actual practice or failure to mention it is unclear. 
Nevertheless, neither group appeared to put much weight on this part of the procedure. 
Informed consent, on the other hand, assumed a greater significance: 80% of the IDUs said 
they had given it, and the majority of SPs explained how they obtained it.  
According to the guidelines, the results of a hepatitis test should always be given face to 
face, whatever the reason for testing or the test outcome. This appeared to be generally 
understood by the SP informants although a few still gave hepatitis results over the phone 
and HIV/AIDS results in person. Most IDU respondents received their results in person, 
although one in ten were telephoned and there were a few horrific stories of other 
approaches. The chronology of these stories, however, has not been assessed, and they 
may have occurred in earlier years before guidelines were developed. 
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In terms of post-test counselling, the guidelines state that the aims are to ensure that the 
patient understands the meaning and implications of the test result, and that appropriate 
referrals and psychosocial interventions occur if required. If the patient is negative, 
counselling should provide information to prevent exposure to the virus, and the individual 
should be assisted to adopt relevant skills to remain infection free. The positive patient 
should be provided with immediate counselling or support and information to prevent 
transmission to others, and the extent of personal support should be assessed. Referral to 
external sources of support such as longer-term counselling or a local Hepatitis C Council 
is recommended.  
The IDUs reported what appeared to be inadequate or non-existent post-test counselling in 
many cases. Post-test counselling was said to have been provided on fewer than 20% of 
most recent test occasions, and where it was provided it was almost always in the context 
of positive results. Even allowing for misunderstandings of the term “post-test 
counselling”, these are disturbing findings.  
Our data suggest that much of the counselling suggested in the guidelines was not 
occurring, and that post-test counselling was primarily used after positive results as a 
medical intervention. Very few IDUs reported counselling following negative results, or 
referral to support agencies. Moreover, as with pre-test counselling, they clearly had little 
tolerance for a lot of discussion once they had a negative result: they felt that they 
understood how to prevent transmission and they wanted to take their results and go. 
Written information was similarly not highly regarded. Some did not collect test results, 
apparently believing that they would be told if anything was wrong. Although this may 
have been an unconscious cover for some underlying anxiety about the result, in some 
cases it was clearly related to the respondent being in (drug) treatment and believing that 
results would be conveyed by the case manager if there was any need.  
SP informants, who, it should be emphasised, were not the same testers as those referred to 
by the IDU respondents, seemed more inclined than testers reported by IDUs, to offer post-
test counselling after negative results, and their descriptions of post-test counselling were 
comprehensive, although not all of them offered all the topics. Their assumptions about 
why IDUs did not collect test results were somewhat different from those given by the IDU 
respondents, and they may have failed to appreciate the extent to which information given 
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to clients should emphasise that blood borne viruses are not like other infections, and test 
results will only be conveyed in person.  
IDU respondents described a range of emotional experiences related to being tested. They 
reported being anxious on almost half of described testing occasions, mainly while waiting 
for results and in some cases because they knew they had engaged in unsafe behaviour. 
Responses to negative test results were, as noted above, often described as relief or delight. 
Those who received positive test results experienced a range of responses, including very 
strong anxiety. It is not clear how their testers responded to their emotional reactions, 
except, of course, that most IDUs said they received no post-test counselling and it may 
have been that their tester did not know how they were feeling. What is clear is that very 
few were referred to local support agencies such as the Hepatitis C Council who would 
have been in a good position to assist them to come to terms with positive diagnoses.  
SP informants had generally observed the same emotions in their clients that IDU 
respondents described. Most said they dealt with these reactions with counselling, 
information provision and referral. The SP informant who said s/he did not deal with 
her/his client’s emotional responses well was being very honest, and it is to be hoped that 
s/he had developed some alternatives mechanisms for supporting positive clients.  
THE CONSEQUENCES OF TESTING  
In the section on reasons for being tested, it was noted that many of the reasons given by 
IDUs for seeking testing were derived from rationales that would have been given to the 
doctor or clinic when requesting the test. Little information was obtained about the 
relationship of the testing process to the needs of the respondent (with the possible 
exception of those who stated they sought testing in connection with a relationship).  
More information about IDUs’ relationship to the testing process was obtained through 
questions about their response to their test results. Respondent’s comments about their 
feelings about negative results often indicated a sense of validation, which suggests that 
the testing process may have served to reinforce current behaviour patterns as being 
behaviours which were “safe”. Respondents who tested positive, on the other hand, often 
seem resigned or unsurprised: they had expected to be positive and the test confirmed it. 
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 Further comments made by both positive and negative respondents about their behaviour 
since last tested demonstrated that there had been no real behaviour change. In some 
instances, where behaviour change had occurred, this was, if anything, in the direction of 
more risk. Those who reported positive behaviour changes were often referring to health 
related change, such as reduced use of drugs or improved diet, which were designed to 
promote the health of the individual rather than reduce transmission of the virus.  
These comments suggest that the IDU respondents had a dichotomous understanding of 
risk: that is, they conceived of any given behaviour as being either safe or risky. Many 
testees described their normal injecting behaviour as safe, particularly when explaining 
why they had not changed their behaviour following testing. While many also admitted 
they had on occasion behaved in ways which they understood to be risky, this was not 
often seen as being part of their current, normal behaviour, although these occasional 
aberrations were high on the list of motivations to seek testing. 
As suggested earlier, both testees and testers also appeared to be acting from an implicit 
quarantine model, in which testing would allow an individual to self-quarantine following 
a positive result. The frequency with which IDU respondents sought testing, the 
commonality of risk-exposure as a motivation to seek testing, and the willingness of testers 
to provide testing to those at risk all support this suggestion.  
Those who tested negative were confirmed in their belief that their normal behaviour was 
safe, as proven by their negative result. They may have explained their negative test result 
following exposure to risk in a number of ways, from luck through to the view that perhaps 
the risk behaviour was not that risky after all. From a quarantine perspective, they may 
have had no motivation to make any behaviour change, because they believed their 
negative status did not put others at risk. 
Those who tested positive may have interpreted this as confirming their suspicions that a 
given event or series of events were the point at which they contracted the BBV in 
question. Normal or current behaviour was not necessarily implicated, which might help 
to explain why the majority of seropositive respondents stated that they had not changed 
their behaviour since their last test, even though a significant number also expressed 
concern about passing the BBV on to others.  
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As has been demonstrated, the efficacy of testing IDUs for BBVs, as it is often currently 
practiced, appears to be hardly related to the test situation being a vehicle for counselling 
and the promotion of behaviour change. The testing process as described by our IDU 
respondents did not actively encourage seronegative IDUs to initiate behavioural change, 
nor did it encourage seropositive IDUs to regard their normal behaviour as behaviour 
which might transmit infection to others.  
HEPATITIS B VACCINATION  
Only 24% of the sample had been vaccinated against hepatitis B. Many of the non-
vaccinated had been tested for hepatitis B and found to be seronegative. Many of those 
who had not been vaccinated, moreover, reported that had never heard of it or been offered 
it. Some did not understand why IDUs were at risk of hepatitis B, or why they should be 
vaccinated. Some were concerned about cost when the experience of those who had been 
vaccinated demonstrated that free vaccination was available. Most of the minority who 
had been vaccinated had completed the course and were pleased that they had done so, 
although it is interesting that some of their reasons for being vaccinated had little to do 
with injecting as a risky lifestyle. Information provision prompted a number of the non-
vaccinated to profess interest in seeking it out.  
As with the reports about test counselling, these results are too strong to be explained away 
as the poor memory of a few IDUs, and are disturbing. It is now 15 years since the 
NHMRC called for all IDUs to be vaccinated because of their high risk status (Gust, 1992) 
and it seems extraordinary that when so many of the respondents in this study had been 
tested because they were IDUs, so few had been vaccinated, particularly when many of 
these had received a negative hepatitis B test. Clearly, opportunities for prevention of this 
disease had been squandered.  
CONCLUSION AND RECOMMENDATIONS  
The cost of a BBVI screen (all three tests) is in the order of $25 – 30. We have seen that 
the SPs ordered many tests each month, and that the tested IDUs had typically had more 
than one test. The majority of IDU respondents had not been vaccinated against hepatitis 
B, despite having been tested and being seronegative. Many claimed they had never been 
told about vaccination. 
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This study has shown that the process of testing, as reported by the IDUs, was, in many 
cases, far from satisfactory. Clients were motivated to avoid behaviour change; test 
service providers were willing to test whenever requested to do so and some testees were 
apparently using testing to prove themselves uninfected: all these findings suggest that 
much testing may not have been serving any purpose other than to diagnose infection and 
implement appropriate medical interventions. While not decrying this as a motivation, it is 
clear that testing for BBVs also provides an ideal opportunity in which doctors and other 
service providers can help IDUs to make the behaviour changes necessary to prevent these 
infections, or to prevent reinfection and/or other complications associated with hepatitis C 
infection. It is also an ideal opportunity in which to encourage IDUs to be vaccinated 
against hepatitis B. Since so many IDUs are tested, the potential for incidence reduction 
and secondary prevention is enormous. 
These comments raise a number of questions, which we believe test service providers 
should be considering when an IDU requests a BBV screen – particularly if the client is 
regularly tested in this way.  
• What is the understanding of the test service provider? That a test event is not only a 
medical, but also a psycho-social intervention to prevent risk behaviour through good 
pre- and post test counselling, follow-up and referral? Or that the test event is primarily 
a medical intervention which is designed to diagnose infection so that it can be treated?  
• What are the expectations of IDU clients? That a test event is an opportunity for them 
to discuss why they believe they could be infected and how they can avoid further risk, 
and establish whether they are infected and if so how they can minimise risk to others 
and maximise their health? Or that a test is a way of establishing whether or not they 
are infected, so that if they can continue with their current practices until or unless they 
become infected?  
• How well do the expectations of the test service provider and the client match? If they 
do not, how can they be brought closer together?  
The resolution of these questions may involve more research. We believe that more 
information is needed from doctors, IDUs and other interested parties about the limitations 
and difficulties with the existing testing guidelines. We have recently received funding to 
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undertake research to develop more detailed recommendations about the testing process, 
and particularly pre- and post-test counselling. Some of the questions to be examined 
include:  
• How appropriate are the current guidelines for either hepatitis C or HIV/AIDS testing, 
when most IDUs undertake these tests in batteries?  
• How relevant are the guidelines to IDUs who are regularly tested?  
• Under what circumstances should the guidelines be followed closely?  
• Under what circumstances are the guidelines not appropriate?  
• What should the role of testing be in promoting change towards safer behaviour? How 
can that best be facilitated?  
• How practical is it to expect GPs, particularly, to implement the guidelines given the 
cost recovery structures of most practices? 
• What are the barriers to the vaccination of IDUs against hepatitis B? How can these 
best be overcome?  
• Are service providers unwilling to suggest vaccination if they believe that clients well 
be put off by the cost? 
The findings of the two studies should enable the development of specific 
recommendations on maximising the efficacy of the testing process to prevent and limit the 
spread of blood borne viruses in injecting drug users in Australia.  
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Questionnaire Number  1-3 
Date         4-7 
Recruited from:_______________  8-9 
 
SECTION A : DEMOGRAPHICS 
 
A1. Are you: 
    Male  1 
    Female 2 
    Transgender 3   
               10 
 
A2.   How old are you?     ......................................... 
                            11-12 
 
A3. What is your current residential postcode?     .............................. 
                   13-16 
 
A4. Are you currently: 
    Single/separated/divorced  1 
    Married/living with sexual partner 2 
                 17 
 
A5. How would you describe your sexual preference? 
 
    Gay/Lesbian   1 
    Straight/Heterosexual 2 
    Bisexual   3 
    Other (specify)  4........................ 
                18 
 
A6.  What is the highest level of education completed? 
     
    
    Junior high (Yr 10) 2 
Primary school 1 
    Senior high (Yr 12) 3 
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    TAFE/Trade/Tech 4 
    University/College 5 
    Other (specify)     6................................... 
              19 
 
A7. How are you employed at the moment? 
     
    Student - secondary 1 (  Q.A9) 
    Student - tertiary 2 (  Q.A9) 
    Full time  3  
    Part time/Casual 4  
    Home Duties  5 (  Q.A9) 
    Unemployed  6 (  Q.A9) 
    Other (specify) 7 ................................... 
              20 
 
 
A8. What is your current job?     .................................................................... 
              21 
 
A9. What is your MAIN source of income? 
 
    Unemployment benefits 1 
    Sickness benefits  2 
    Pension   3 
    Drug dealing   4 
    Job    5 
    Other illegal activities 6 
    None    7 
    Other (specify)       8.............................. 
              22 
 
A10.   What country were you born in? 
     
    Australia  1 
    Other (specify)      2.......................................... 
              23 
 
A11. Are you of Aboriginal or Torres Strait Islander descent? 
 
    Yes 1 
    No 2 
              24 
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A12. What language was the main one spoken at the home you grew up in? 
 
    English  1 
    Other (specify) 2............................................. 
              25 
 




SECTION B: DRUG USE BEHAVIOUR          New Record 
 
B1.  Have you: 
 
 















01 Alcohol       
02 Benzodiazepines       
03 Cannabis        
04 Hallucinogens       
05 Heroin       
06 Methadone       
07 Amphetamines       
08 Ecstasy       
09 Steroids       
10 Other       
    1-10          11-20       21-30    31-40  41-49  50-58 
Other=______________________________________________________________________(other opiates = 11) 
 
* detox = 1          RR/TC = 2          meth = 3          GP = 4          couns = 5          NA = 6          hosp = 7          other = 8 
 
B2. At what age did you first inject? __________ 
              59-60 
B3. When did you last inject? ___________ 
        61-63 
B4. What is the main drug that you inject?_________________________ 
         64-65 
B5. What drug did you last inject?_______________________________ 
         66-67 
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B6. How frequently do you inject (in a typical week in the last month)/before you  were 
 in treatment? 
 
    More than 2-3 times a day 1 
    Once a day   2 
    Every second day   3 
    Twice a week   4 
    Once a week   5 
    Less frequently  6 
    Not at all   7 
               68 
 
Wanring: New Record 
New Record 
SECTION C: RISK TAKING BEHAVIOUR 
 
 
C1. How often have you injected a drug in the past month? 
 
    Haven't had a hit   1  (  Q.C7) 
    Less than once a week 2 
    Once a week   3 
    More than weekly, not daily   4 
    Once a day   5 
    2-3 times a day  6 
    More than 3 times a day 7 
              1 
 
 
C2. How many times in the past month have you used a needle after someone else 
 (including your lover)  has already used it? 
 
    Never   1 
    Once   2 
    Two times  3 
    3-5 times  4 
    6-10 times  5 
    More than 10 times 6 
              2 
 
 
C3. What is the total number of people (including your lover) who have used a needle 
 before you in the past month? 
 
    None   1 
    One    2 
NCRPDA - BBV and Testing Study:  IDU Interview '97 4 
    Two    3 
    3-5    4 
    6-10    5 
    More than 10  6 
              3 
 
C4. How many times in the past month has someone else (including your lover) used a 
 needle after you have used it? 
 
 
    Never   1 
    Once   2 
    Two times  3 
    3-5 times  4 
    6-10 times  5 
    More than 10 times 6 
              4 
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C5. In the past month which of the following people have you shared a needle with? 
    Regular sex partner   1  5 
    Close friend    2  6 
    Casual sex partner   3  7 
    Someone I don't know very well 4  8 
    No-one    5  9 
    Other (specify)..................................6  10               
C6. How many times in the past month have you shared other injecting equipment (eg 
 spoons, filters, water, tourniquet) with someone else (including your lover)? 
 
    Never   1 
    Once   2 
    Two times  3 
    3-5 times  4 
    6-10 times  5 
    More than 10 times 6 
              11 
C7. How many people have you had vaginal/anal intercourse with in the past month? 
 
    None   1  (  Q.D1) 
    One    2 
    Two    3 
    3-5    4 
    6-10    5 
    More than 10  6 
              12 
C8. If you had intercourse in the past month how often did you or the person you had  sex 
with use condoms? 
 
    Never   1 
    Rarely  2 
    Sometimes  3 
    Often   4 
    Every time  5 
    No intercourse 6 
              13 
C9. In the past month which of the following people have you had intercourse with? 
 
    Regular sex partner   1  14 
    Close friend    2  15 
    Casual sex partner   3  16 
    Someone I don't know very well 4  17 
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    No-one     5  18 
    Other (specify)..................................6  19 
 
 
SECTION D - KNOWLEDGE 
 
D1. Do you think that HIV/AIDS is a risk for IDUs? 
 
    Yes   1  
    No   2  
                 20 
 








D2. Do you think that HCV is a risk for IDUs? 
 
    Yes   1  
    No   2  
                 21 
 








D3. Do you think that HBV is a risk for IDUs? 
 
    Yes   1  
    No   2  
                 22 
 


















SECTION E: HIV 
 
E1. Have you ever had a HIV/AIDS test? 
 
    Yes 1 (  Q.E3) 
    No  2 (  Q E2) 
              23 
 









(  Q.E10) 
 
E3. How many HIV/AIDS tests have you had? ____________________       24-25 
 
 
E4. How many times have you had a HIV/AIDS test on it's own?_________    26-27 
 (if always in a battery, rest of the questions apply to all tests - HBV, HCV, HIV) 
 
 
E5. When was your first HIV/AIDS test? _____/_____/_____ mths  28-30 
 
E6. When was your last HIV/AIDS test? _____/_____/_____ mths  31-33 
 
 
E7. Where was your last test? _______________________________________ 
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E8. How often do you get tested? (At what intervals) ____________________ 
 
 
E9. What was the result of your last HIV/AIDS test? 
 
    Antibody positive  1 (  Q E13) 
    Antibody negative  2 (  Q E11) 
    Unclear/Indeterminate 3  (  Q E11) 
    Don't know - didn't pick up 4  (  Q E10) 
    Refusal   5 
    Other (specify)  6...............................   
              34 
 
 










E11. Do you think you are now antibody positive for HIV/AIDS?  
 
    Yes  1          
    No   2   
              35 




















(if not tested  Q.E24) 
 
E13. Why did you decide to get tested for HIV/AIDS? (1st time; other times) 


































(c)  Confidentiality?  Was this explained?  HDWA notification process explained? 
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How were you treated? (by who?) 






WHAT ABOUT FOR OTHER TEST INCIDENTS? - anything else you want to tell me about 





































 (not just the result) 
15. Have you ever had a bad experience when being tested for HIV /AIDS? 
    Yes  1          
    No   2 (  Q E16)   
            36 
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If HIV+   Q E17;  if HIV-   Q E18 
 
 
E17. What effect does your positive HIV/AIDS serostatus have on your life?   









(  Q E19) 
 
E18. What effect does your negative HIV/AIDS serostatus have on your life? 
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E19. Was there any change in your behaviours after you received your last result? 
 (treatment, lifestyle) 
    Yes 1 (  Q.E20) 
    No 2 (  Q.E23) 
              37 
 


















(if forever  Q.E24) 
 
 









(  Q.E24) 
 
 

















E24. Have you ever refused to be tested for HIV/AIDS when it has been 
 recommended? 
    Yes  1          
    No   2 (  Q.E25) 
              38 
 










E25. Have you ever been refused HIV/AIDS testing when you have requested it? 
 
    Yes  1          
    No   2 (  Q.F1) 
              39 
































Warning: New Record 
 
New Record 
SECTION F: HCV 
 
F1. Have you ever had a hepatitis C test? 
 
    Yes 1 (  Q.F3) 
    No 2 (  Q.F2) 
              1 
 









(  Q.F10) 
 
F3. How many hepatitis C tests have you had?   ____________________           2-3 
 
F4. How many times have you had a  HCV test on it's own? __________            4-5 
 
 
F5. When was your first hepatitis C test? _____/_____/_____ mths      6-8 
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F7. Where was your last test?_______________________________________ 
 
 
F8. How often do you get tested? (At what intervals) ____________________ 
 
 
F9. What was the result of your last HCV test? 
 
    Antibody positive  1 (  Q F13) 
    Antibody negative  2 (  Q F11) 
    Unclear/Indeterminate 3  (  Q F11) 
    Don't know - didn't pick up 4 (  Q F10) 
    Refusal   5 
    Other (specify)  6..............................  
      
              12 
 










F11. Do you think you are now antibody positive for hepatitis C?  
     
    Yes  1          
    No      2          
               13 
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(if not tested  Q F24) 
 
F13. Why did you decide to get tested for hepatitis C?  (1st time; other times) 



















NCRPDA - BBV and Testing Study:  IDU Interview '97 18 
PROMPTS : 
 













(c)  Confidentiality?  Was this explained?  HDWA notification process explained? 






























(h)  Were you referred anywhere else?  Where?  What about follow-up? 
 




























WHAT ABOUT FOR OTHER TEST INCIDENTS? - anything else you want to tell me about 






































 (not just the result) 
15. Have you ever had a bad experience when being tested for HCV? 
    Yes  1          
    No   2 (  Q F16) 
              14 






















If HCV+   Q F17;  if HCV-   Q F18 
 
 
F17. What effect does your positive HCV serostatus have on your life?   
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 (  Q F19) 
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F19. Was there any change in your behaviours after you received your result? 
 (treatment, lifestyle) 
    Yes 1 (  Q.F20) 
    No 2 (  Q.F23) 
              15 
 
 


















(if forever   Q F24) 
 
 









(  Q F24) 
 
 

















F24. Have you ever refused to be tested for HCV when it has been recommended? 
 
    Yes  1          
    No   2 (  Q F25) 
              16 
 










F26. Have you ever been refused HCV testing when you have requested it? 
 
    Yes  1          
    No   2 (   Q G1) 
              17 
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SECTION G: HBV 
 
G1. Have you ever had a hepatitis B test? 
 
    Yes 1 (  Q.G3) 
    No 2 (  Q.G2) 
              18 
 









(  Q.G10) 
 
G3. How many hepatitis B tests have you had?   ___________________          19-20 
 
G4. How many times have you had a HBV test on it's own? ___________        21-22 
 
 
G5. When was your first hepatitis B test? _____/_____/_____ mths  23-25 
 




G7. Where was your last test?_______________________________________ 
 
 
G8. How often do you get tested? (At what intervals) ____________________ 
 
 
G9. What was the result of your last HBV test? 
 
    Antibody positive  1 (  Q G13) 
    Antibody negative  2 (  Q G11) 
    Unclear/Indeterminate 3  (  Q G11) 
    Don't know - didn't pick up 4 (  Q G10) 
    Refusal   5 
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    Other (specify)  6..............................  
      
              29 
 
 










G11. Do you think you are antibody positive for hepatitis B?   
     
    Yes 1          
     No   2 
              30 



















(if not tested  Q G24) 
 
G13. Why did you decide to get tested for hepatitis B? (1st time; other times) 



































(c)  Confidentiality?  Was this explained?  HDWA notification process explained? 
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WHAT ABOUT FOR OTHER TEST INCIDENTS? - anything else you want to tell me about 







































 (not just the result) 
15. Have you ever had a bad experience when being tested for HBV? 
    Yes  1          
    No   2  (  Q G16) 
              31 










G16. Tell me how you felt when you found out your last HBV test result: 











If HBV+   Q G17;  if HIV-   Q G18 
 
 
G17. What effect does your positive HBV serostatus have on your life?  









(  Q G19) 
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G19. Was there any change in your behaviours after you received your result? 
 (treatment, lifestyle) 
   Yes 1 (  Q.G20) 
   No 2 (  Q.G23) 
              32 
 
 


















(if forever  Q.G24) 
 
 









(  Q.G24) 
 
 

















G24. Have you ever refused to be tested for HBV when it has been recommended? 
 
    Yes  1          
    No   2 (  Q.G25) 
              33 
 










G23. Have you ever been refused HBV testing when you have requested it? 
 
    Yes  1          
    No   2 (  Q.H1) 
              34 
 

































SECTION H: HBV VACCINATION 
 
H1. Have you been vaccinated against hepatitis B? 
 
    Yes   1 (  Q.H6) 
    No   2 (  Q.H2) 
    Don't know  3 (  Q.H5) 
    Never heard of vax 4 (  Q.H14) 
    HBV +ve: immune 5 (  Section I) 
              1 
 


















H4. Are you more careful because you haven't been vaccinated? 
 
     Yes 1 
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     No 2 (  Q.H14) 
              2 







(  Q.H14) 





















H7. How long ago were you vaccinated? ____________________ mths        3-5 
 
 











H9. Did you finish the whole course? 
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    Yes  1   
    No  2   
    Don't know 3 
              6 
 Why/why not? _____________________________________________________ 
 







H10. Over what period did the course take place?  ___________________________ 
 
 
H11. Did you have to pay?  
  
    Yes 1   How much? $__________/shot 
    No 2   

















H13. What difference does it make to your life if you've been vaccinated?  












EDUCATION SESSION ON HBV VACCINATION 
 
 
H14. Now that you know a bit more about HBV vaccination, would you consider being 
vaccinated? 
     Yes   1 
     No   2 
     Don't know  3 
     Been vaccinated 4 












 (where, when??) 
 
 
SECTION I: HEALTH PROMOTION. HARM REDUCTION MESSAGE 
 
Give referral sheet. 
 
Plus info on: blood awareness;  safer injecting and sex;  basic transmission info 
 











How co-operative did you find the interviewee? 
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How truthful did you think the interviewee was? 
 


























NATIONAL CENTRE FOR RESEARCH INTO THE PREVENTION OF DRUG ABUSE  
GPO BOX U1987, PERTH   WA   6001 
TELEPHONE: 09 368 2055 FAX: 09 367 8141
 
TESTING FOR BLOOD BORNE VIRAL INFECTIONS IN INJECTING 
DRUG USERS 
 
Project Director:  Dr Wendy Loxley           Project Officer: Paige Sullivan 
 
TO:  FROM:    Paige Sullivan   
   
 
NUMBER:  DATE:      
 
TOTAL PAGES SENT:  4       
 
I am writing in regard to our recent telephone conversation in which I informed you of the 
above study and you agreed to be one of the key service providers to be interviewed.  Could 
you please fill in the following questions within one week from today (by by Monday 26 
May), and fax it back with your answers.  Could you please fax back this coverpage 
ASAP so I can schedule your interview.  Please keep a copy of this questionnaire for further 
discussion during the interview.  I will then inform you of the time of your half hour 
telephone interview by phone, and look forward to speaking to you again at this time.  Thank 





Paige Sullivan, Project Officer   
 
Please circle the times most suitable for you to undertake a thirty minute follow up 
phone interview. I will work out the interstate time differences accordingly  
(please circle more than one). 
 
Tuesday 3 June 10am     11am     1pm     2pm     3pm      
 
Wednesday 4 June 10am     11am     1pm     2pm     3pm      
 
Thursday 5 June 10am        *       1pm     2pm     3pm      
 
Friday 6 June 10am     11am     1pm     2pm     3pm      
 
Monday 9 June   *        11am     1pm     2pm     3pm      
 
Tuesday 10 June 10am     11am     1pm     2pm     3pm      
 
Wednesday 11 June 10am     11am     1pm     2pm     3pm      
 
Thursday 12 June  10am      *        1pm     2pm     3pm  
 
Friday 13 June  10am     11am     1pm     2pm     3pm  
1 
 
Monday 16 June   *        11am     1pm     2pm     3pm  
 
Tuesday 17 June      10am     11am     1pm     2pm     3pm 
 
Wednesday 18 June  10am     11am     1pm     2pm     3pm 
 
* I am unavailable. 
 


















SECTION A: DEMOGRAPHICS AND STATISTICS -  ID Number  
 
A1. How many staff members at your agency/practice are involved in testing injecting 













A3. On average, how many individual clients does your agency/practice see per month?  






A4. Approximately how many of those clients self disclose that they are current or past 







A5. What is the approximate range in ages for clients having blood borne virus tests at 






A6. What is the approximate gender breakdown for clients having blood borne virus tests 
















 Which HBV tests do you request? 
 
  
Test Please tick Circumstances 
Surface Antigen   
Antibody   
Core   




A8. On average, how many Hepatitis C antibody tests are done in your agency/practice per 
































A11. Approximately what percentage of your BBV tested IDU clients are: 
 
   Referred by GPs and other agencies? __________%  
 
   Self-referred/Off the street?   __________%  
 
   Referral source unknown?   __________%  
  
 
SECTION B:  TRAINING AND KNOWLEDGE 
 
B1. Do professional staff receive training on blood borne viruses? (please circle)   Yes     
No 
 










B2. Do professional staff receive training on IDUs? (please circle) Yes       No 
 











































Please fax back the cover sheet with your interview time preferences ASAP.  
Please fax the completed questions by Monday 26 May 1997 on (08) 9367 
8141.  Thank you for your time. 
Date __________         Time: start__________finish_________      ID Number: 
 
 
BBV AND TESTING STUDY:  SERVICE PROVIDER INTERVIEW SCHEDULE 
 






SECTION C:  PROTOCOLS/POLICIES/GUIDELINES 
 
 
C1. What stages of the testing process are done in the agency?  
 
  pre-test counselling  
  taking blood   
  post-test counselling  
  referral  




C2. In what circumstances are current and past IDUs tested for BBVs   












C3. Do clients ever refuse to have a BBV test after being advised to? Yes No 
 














C4. Do you ever refuse to test a client? Yes No 
   
















C5. How do you ensure the client's informed consent for a BBV test?  














C6. Is pre- and post-test counselling provided for a BBV test? 
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C9. What is covered in pre- and post-test counselling for BBVs?  
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C10. Are written info/resources are provided to the client? Yes No  
 
 












C11. How are the results usually given for BBV test? (face to face, phone, written)  




















C13. What happens if clients don't pick up their results?   
 
 









C14. What happens after a positive test result has been given?   












C15.   What happens when a clients requests re-testing? (How much is asked about 










C16. Do you ever refuse to re-test a client? Yes No 
 











C17. At what intervals  do you suggest clients be re-tested?  
 












C18. What practices are undertaken to ensure the client's confidentiality?  (What are 













C19. Do you have a policy for control of intoxicated or difficult clients?       Yes      No    
 














SECTION D:  HEPATITIS B VACCINATIONS 
 
D1. What is the nature of clients that get vaccinated?  
 (IDU? Gay men? Sex workers? Youth? Other?) 
   
 
  





D2. How does a hep B vaccination usually come about?  

































D5. Is there a cost to the client for hep B vaccination ? Yes No 
 
 
 If so, how much is charged?  $_______________ 
 
 
 Do you think the cost of hep B vaccine is diffcult for clients? Yes No 
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SECTION E:  IDUS 
 
 

















E2. For those who self-refer for testing, what are the range of things that you believe 

















E3. Do you believe some IDUs need to be advised to be tested/vaccinated?   Yes    No 

































E5. In your experiences, what is the range of emotional responses by IDU clients to 
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